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STAPHYLOCOCCUS AUREUS, AND ESCHERICHIA COLI 
 
Christopher Ryan Howe 
 
In 2019, the ESKAPE pathogens were highlighted by the World Health 
Organization as some of the most prominent threats to human health, capable of 
developing significant antibiotic resistance. These pathogens contribute to over 2 million 
annual infections and ~23,000 annual deaths in the U.S. In addition, various strains of E. 
coli have also shown a proclivity to develop resistance against common drug classes. 
The prevalence of these infections highlights an urgency to discover new antibiotics that 
target previously unexploited pathways essential to bacterial survival. 
The bacterial GroEL/ES chaperonin system is viewed as a viable antibiotic 
target. It has been proven essential to bacterial survival and homeostasis under all 
conditions. Previous studies identified hit GroEL/ES inhibitors with potential antibiotic 
activity. One promising hit (1) was shown to be a moderate but selective GroEL/ES 
inhibitor with antibacterial effects against Gram-negative pathogens (K. pneumoniae and 
A. baumannii). The structural similarity of 1 to known antibiotics – nitroxoline, 
nifuroxazide, and nitrofurantoin – prompted me to develop two series of 
hydroxyquinoline and nitrofuran-based analogs. I then assessed these compounds’ 
abilities to inhibit in vitro GroEL/ES activity, as well as to selectively target ESKAPE/E. 
coli bacteria over human cells. Initially, I found the nitrofuran analogs were stronger 
inhibitors of bacterial growth than the hydroxyquinolines, but were weaker at blocking 
GroEL/ES functions. However, considering nitrofuran-based antibiotics behave as pro-
drugs, it was found that they became much more effective GroEL/ES inhibitors when E. 
vii 
coli NfsB nitroreductase was introduced into the GroEL/ES-dMDH refolding assay, 
metabolizing the nitro groups to their active species. Importantly, lead analogs that 
potently inhibited bacterial growth exhibited low cytotoxicity to human colon and intestine 
cells. Although I found E. coli were able to generate varying degrees of irreversible 
resistance to nifuroxazide, nitrofurantoin, and lead inhibitor 17, perhaps through 
mutations known to effect NfsA and NfsB nitroreductases, the resulting strains were not 
necessarily cross-resistant to the other inhibitors. Thus, combination therapy may help 
bypass these resistance mechanisms. 
In summary, this study identified key structure-activity relationships to selectively 
inhibit GroEL/ES and the growth of several bacterial species. Results from this study will 
aid future efforts to improve inhibitor potency.  
 
 
 
Steven M. Johnson, Ph.D., Chair 
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INTRODUCTION 
The rise of antibiotic-resistant bacteria 
The emergence of antibiotic-resistant bacteria has become a significant threat to 
human health. A 2019 CDC report titled “Antibiotic Resistance Threats in the United 
States”1  touches on the dangers of the ESKAPE pathogens, which consist of Gram-
positive Enterococcus faecium and Staphylococcus aureus, as well as Gram-negative 
Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacter species. These are a subset of bacteria that are prone to developing 
resistance against commonly used antibiotics. The ESKAPE pathogens contribute to 
approximately two-million infections in the U.S. per year, as well as nearly 23,000 annual 
deaths.2  In addition to the ESKAPE pathogens, multiple strains of Gram-negative 
Escherichia coli have also shown a tendency to threaten public health through antibiotic 
resistance. One particular class of E. coli, the resistant Shiga-toxin producing (STEC) 
pathogens, was noted as the chief cause of over 265,000 infections in the U.S., in 2018.3  
It also appears that STEC infections have become more common over the past 20 
years, as these pathogens were linked to far fewer (~110,000) U.S. infections in 1999.4 
Although the majority of E. coli infections take place in the urinary tract (known as UTIs), 
these infections can eventually spread to the kidneys and the bloodstream. This can 
lead to painful symptoms, such as bloody urination and sepsis. The persistence of 
ESKAPE and E. coli infections is quite alarming, as it offers the potential for long-term 
health concerns in the community. Thus, it is crucial that novel antibiotics are developed 
to combat their proliferation in susceptible populations, which include hospital patients 
and the immunocompromised, among others.  
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Current antibiotic classes and a lack of antibiotic variety 
In 1928, Sir Alexander Fleming discovered the first known antibiotic drug, 
penicillin, which provides activity against bacterial cell wall synthesis by inhibiting D,D-
transpeptidase, a crosslinking enzyme.5 At the time of Fleming’s initial discovery, 
penicillin could not be produced for the masses because of a lack of technological 
means. That changed just 16 years later during World War II. A collaborative effort, 
headed by the Allied Power pharmaceutical companies, sought to produce larger 
quantities of penicillin for ailing soldiers. This initiative ultimately led to the production of 
2.3 million doses of penicillin for D-Day in Normandy.5 Not only was this beneficial to the 
war effort, but it also demonstrated that the world was ready to mass produce antibiotics 
for public use.  
The ability to mass produce penicillin prompted scientists to search for additional 
classes of antibiotics with different protein targets. For instance, the sulfonamides were 
discovered in the 1930’s.6 Sulfonamides are known for their ability to mimic para-
aminobenzoic acid (PABA), an intermediate in the bacterial folic acid synthesis pathway. 
These antibiotics outcompete PABA for dihydropteroate synthetase, leading to 
downstream inhibition of folic acid synthesis. In the 1940’s and 1950’s, tetracyclines and 
macrolides were developed.7,8 These classes of antibiotics are primarily linked to 
inhibition of bacterial peptide synthesis pathways. Tetracyclines bind to the 30S 
ribosomal subunit to block aminoacyl-tRNA occupation of the A-site, whereas macrolides 
bind to the 50S subunit to block the ongoing development of the growing peptide chain. 
In the 1960’s, fluoroquinolones came into prominence as strong inhibitors of the major 
bacterial transcription enzymes Topoisomerase IV and DNA gyrase.9 The general 
scaffolds/structures for these antibiotics and their associated mechanisms of action are 
shown in Figure 1A-D.10-12  
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Figure 1 – Mechanisms of action for commonly used antibiotics General mechanisms of 
action of several current antibiotic classes. Associated “R” groups represent a variety of functional 
groups that are typically attached to these core scaffolds. 
A. Sulfonamides mimic PABA, acting as an antagonist of dihydropteroate synthetase. As a 
result, they inhibit downstream folic acid synthesis in bacteria.                     
 
 
 
 
 
 
 
 
B. Tetracyclines block peptidyl synthesis in bacteria by binding to the ribosomal 30S subunit 
(occupying the A site). This prevents the delivery of the aminoacyl-tRNA component to 
the ribosome.10 
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C. Macrolides block peptidyl synthesis in bacteria by binding to the ribosomal 50S subunit 
(occupying the P site). This disrupts the continuous addition of amino acids to the 
growing peptide chain.11 
 
 
 
 
 
 
 
 
 
 
D. Fluoroquinolones inhibit DNA Topoisomerase IV and DNA gyrase enzymes, which are 
involved in the unwinding of double-stranded, circular bacterial DNA (in preparation for 
transcription).12 
 
 
 
Although these antibiotic classes were initially very effective, they soon 
experienced resistance in various bacterial species, including the ESKAPE pathogens 
and E. coli. For instance, resistance was seen against the sulfonamides in the late 
1930’s,6 the penicillins in 1940,6 the tetracyclines in the mid-1950’s,7 and the macrolides 
in 1967.8 Alarmingly, these initial instances of resistance did not occur very long after the 
respective antibiotic classes had been discovered. A similar trend has been seen in 
other antibiotic classes, as well. There are many mechanisms through which bacteria 
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develop antibiotic resistance, many of which are quite common across bacteria and are 
discussed below.                
 
Mechanisms of resistance in ESKAPE pathogens and E. coli 
The ESKAPE pathogens and various strains of E. coli are prone to developing 
antibiotic resistance through a variety of mechanisms. One such mechanism includes 
synthesis of extended spectrum β-lactamases (e.g. AmpC in P. aeruginosa and E. 
cloacae; TEM in E. coli and K. pneumoniae; CTX-M in K. pneumoniae, Enterobacter 
species, E. coli). These specialized enzymes act to hydrolyze drugs with β-lactam rings 
(penicillins, cephalosporins, etc.), thus rendering them ineffective.13,14  In addition, 
pathogens can overexpress efflux pumps (e.g. AcrA-AcrB-TolC in E. coli, MexAB-OprM 
in P. aeruginosa, AdeABC in A. baumannii), which are membrane-spanning machinery 
used to remove toxic substances, including antibiotics, from the cytosol.13,14  Efflux 
pumps have been linked to fluoroquinolone, tetracycline, macrolide, and β-lactam drug 
resistance, among others.13,14 Bacteria can also mutate genes involved in the production 
of porin structures (e.g. OmpF, OmpC, and PhoE in E. coli, as well as OprD in P. 
aeruginosa).14  Polar antibiotics, such as the β-lactams, tetracyclines, and some 
fluoroquinolones, require porins to bypass the highly lipophilic cell membrane and enter 
the bacterial cell. Mutant porins significantly hinder this process, leading to reduced 
antibiotic efficacy. In addition, bacteria can produce variants of the D,D-transpeptidase 
enzyme, which typically drives the final cross-linking step in cell wall synthesis (D-
Ala4→mDAP3, where mDAP (meso-Diaminopimelic acid) is a derivative of lysine with an 
epsilon-carboxy group substitution). Mutant forms of D,D-transpeptidase can be 
produced (e.g. PBP2a in S. aureus, PBP5 in E. faecium)13,15-16, which typically fold in a 
manner that shields the  enzyme’s active site pocket from β-lactam drugs. Even 
alternative forms of D,D-transpeptidase can be developed (e.g. L,D-transpeptidase in E. 
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faecium, as shown in Figure 2), containing different cross-linking substrates altogether 
(L,D-transpeptidase links mDAP3→mDAP3, as opposed to D-Ala4→mDAP3).17  
In addition to acquired resistance, many bacteria are prone to intrinsic resistance. 
For instance, Gram-negative bacteria are structurally less permeable to drugs than 
Gram-positive pathogens, owing to their additional lipopolysaccharide (LPS) outer 
membrane (Figure 3). 18-19 The lipopolysaccharide extensions undergo cross-linking, a 
process that ultimately leads to decreased bacterial membrane fluidity and further 
reduced cell penetrability (Figure 3).18,20  Several of the pathogens from this current 
study are Gram-negative (notably K. pneumonia, A. baumannii, P. aeruginosa, E. 
cloacae, and E. coli), indicating that they present this additional barrier in drug 
development.   
 
Figure 2 – L,D-transpeptidase vs. D,D-transpeptidase mechanism of action Illustration of the 
differences between L,D-transpeptidase (cysteine active site) and D,D-transpeptidase (serine 
active site) activity. L,D-transpeptidase initiates cross-linking between m-DAP3 and m-DAP3, 
whereas D,D-transpeptidase initiates cross-linking between D-Ala4 and m-DAP3. Bacteria can 
evade the activity of β-lactam antibiotics (which target D,D-transpeptidase), by producing the 
alternative L,D-transpeptidase form.13 
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Figure 3 – Gram-positive and Gram-negative bacteria structural differences Structural 
differences between the cell walls of Gram-positive and Gram-negative bacteria, which promote 
intrinsic resistance in Gram-negative forms.18 
 
To make matters worse, antibiotics research has continued to decline in recent 
decades, leading to a depleted drug pipeline. For instance, from 1980-1984, roughly 19 
new molecules gained drug status.21 This dropped to just 6 molecules during the 2010-
2014 time frame (Figure 4).21  A perceived lack of monetary incentive has caused 
pharmaceutical companies to veer away from this area of research in favor of more 
profitable diseases.21 The diminished drug pipeline has created a scenario where there 
are not enough new antibiotics to replace ones that have steadily lost efficacy due to 
bacterial resistance. This indicates a necessity to develop new antibiotics that can target 
novel protein systems central to all Gram-positive and Gram-negative species in order to 
combat a broader spectrum of pathogens.  
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Figure 4 – Reduction in the antibiotic pipeline The antibiotic pipeline has decreased 
throughout the past few decades.21 
 
 
 
 
 
 
 
 
 
 
 
Considerations for GroEL/ES chaperonin systems as antibacterial targets 
A promising and largely unexplored class of targets for new antibiotics is the 
chaperone proteins. These proteins possess two main functions in the cell. The first 
function is to help fold nascent peptides into functional (native) proteins.22 The second 
function is to guide misfolded peptides to the proteasome for degradation, which 
prevents aggregate formation and associated cell toxicity.22  In particular, the Johnson 
lab’s focus is on the bacterial GroEL/ES chaperonin system. GroEL consists of two 
homo-heptameric rings that are stacked back-to-back with each other, which functions 
with the GroES co-chaperone that acts as a lid to cap off the GroEL folding chambers.23  
Targeting GroEL/ES chaperinin systems offer tremendous potential for developing new 
antibiotics because they have been shown to be essential to bacterial cell survival under 
all conditions.24   
The intricate GroEL/ES folding mechanism is initiated when a nascent peptide 
binds to the apical domains of one of the GroEL rings. ATP binding to each of the seven 
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subunits of this cis-ring creates an upward conformational shift in the apical domains, 
allowing them to engage with the GroES co-chaperone.22 Binding of GroES causes a 
greater conformational movement that releases the bound polypeptide substrate into the 
now enclosed GroEL/ES chamber.22 The polypeptide is allowed to try and refold on its 
own, sequestered from the outside cytoplasmic milieu, with ATP hydrolysis (~5-10 s) 
acting as the timing mechanism. ATP hydrolysis in the cis-ring sends an allosteric signal 
for ATP and another unfolded polypeptide substrate to then bind to the GroEL trans-
ring.22 This initiates the release of the GroES lid from the cis-ring, along with the 
folded/native protein.25  If the protein is not in its native state, it can undergo the folding 
process again or be targeted for degradation. A diagram of the GroEL/ES chaperone 
structure is illustrated in Figure 5,26 with a diagram depicting the GroEL/ES-mediated 
polypeptide substrate folding pathway in Figure 6.27 
 
Figure 5 – GroEL/ES structure The structure of GroEL/ES, shown from both side views and top-
down views Two GroEL rings are stacked on top of each other, and each contain an equatorial 
(blue), intermediate (green), and apical (red) domain. The GroES lid component is mobile and 
can translocate between GroEL apical domains.26 
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Figure 6 – GroEL/ES refolding pathway steps The functionality of GroEL/ES is shown, 
including individual steps in the chaperonin-mediated polypeptide substrate folding process. A 
GroEL cis-ring binds a nascent peptide via its apical domain. ATP then binds to the equatorial 
domain of that ring, creating an upward conformational shift. This conformational shift allows 
GroES to bind to the GroEL apical domains, which releases the peptide substrate into the 
chaperone chamber. An ~5-10 second ATP hydrolysis event acts as a timing mechanism for the 
peptide to fold itself. After ATP hydrolysis in the GroEL cis-ring, ATP and another substrate 
polypeptide then bind to the GroEL trans-ring. This causes the GroES lid to be released from the 
cis-ring, along with the potentially folded peptide.27 
             
The universal role of GroEL/ES in bacterial cell survival (both Gram-positive and 
Gram-negative forms) makes it a great target for exploitation by small-molecule 
inhibitors. A potential caveat for this strategy could be off-target effects against HSP60, 
the human isoform of bacterial GroEL, which share 48% sequence identity.28  Despite 
significant homology between the two chaperones, ongoing studies continue to 
emphasize the finding that even compounds that inhibit both bacterial GroEL/ES and 
human HSP60/10 in vitro can be viable antibacterial candidates.28-32 In particular, the 
Johnson lab has identified numerous known drugs and natural products that can target 
both GroEL/ES and HSP60/10 in vitro, yet show low-to-no toxicity in cells or in vivo. For 
instance, it was discovered that suramin, an antibiotic that has been used to treat 
Trypanosoma brucei infections for over 100 years, is a potent GroEL/ES and HSP60/10 
inhibitor in these in vitro assays. This is putatively because such inhibitors cannot 
traverse the highly impermeable mitochondrial membrane to even interact with 
HSP60/10 in the mitochondrial matrix of human cells.29   
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Previous studies to identify GroEL/ES inhibitors with anti-bacterial effects against 
the ESKAPE pathogens 
In 2014, the Johnson lab reported a study that identified 235 GroEL/ES inhibitors 
from a high-throughput screen of 700,000 compounds.33  Subsequent screening and 
med-chem development of two hit-to-lead series, based on scaffolds of 43 and 44 
(Figure 7), identified lead compounds that were able to potently inhibit the proliferation 
of E. faecium and S. aureus bacteria (both Gram-positive), but that were largely 
ineffective against E. coli and the KAPE Gram-negative bacteria.28,31-32 However, from 
initial antibacterials testing,28 compound 1 stood out as another hit inhibitor of interest. 
Despite being only a moderate GroEL/ES inhibitor, 1 demonstrated weak-to-moderate 
inhibition of two Gram-negative ESKAPE pathogens, K. pneumoniae and A. 
baumannii.28  Furthermore, the scaffold of compound 1 resembles other known 
antibiotics that are active against Gram-negative bacteria. For instance, 1 shares its 
main hydroxyquinoline group (circled red in Figure 8) with nitroxoline, an antibiotic that 
is currently used to treat E. coli-based urinary tract infections (UTI’s) and has also 
demonstrated bioactivity against A. baumannii, P. aeruginosa, and K. pneumoniae.34 
Furthermore, compound 1 shares its N-acyl hydrazone core component (circled blue in 
Figure 8) with nitrofuran-based antibiotics such as nifuroxazide and nitrofurantoin, which 
are used to treat E. coli-based UTI’s.35  The one aspect nifuroxazide and nitrofurantoin 
possess that 1 does not, however, is a nitrofuran group (circled green, Figure 8), which 
is known to be key to eliciting antibacterial effects.    
 
  
12 
Figure 7 – Structures of hit-to-lead inhibitors 43, 44, and 1 The structures of hit-to-lead 
antibacterial candidates 43, 44, and 1.  
 
Table 1 – Assay results for high-throughput hits Previously reported biochemical and 
bacterial growth inhibition results for compounds 43, 44, and 1.28,31-32 While analogs of 43 and 44 
were effective against Gram-positive bacteria (e.g. E. faecium and S. aureus), they were largely 
ineffective against Gram-negative bacteria. However, another hit identified from high-throughput 
screening, compound 1, showed weak-to-moderate inhibition of K. pneumonia and A. baumannii 
(Gram-negative bacteria). 
  
 
 
 
 
 
 
 
 
 
 
Based on the similarities of compound 1 with nitroxoline (i.e. hydroxyquinoline) 
and nifuroxazide/nitrofurantoin (N-acyl hydrazones, albeit with nitrofuran substructures), 
I compiled a library of analogs that probed the structure-activity relationships (SAR) of 
the cyclic/aryl substructures on both the right and left-hand sides of the N-acyl 
hydrazone linker. The left side of these analogues contained either a nitrofuran group 
(mimicking nifuroxazide and nitrofurantoin) or a hydroxyquinoline group (mimicking 1 
and nitroxoline), generating two distinct series of compounds. For each series, 15 right 
side R-groups were assessed that contain a diverse range of substructures including 
some that were found to be effective with other GroEL/ES inhibitor scaffolds (see Figure 
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8 for the respective substructures). These analogues were tested in a panel of in vitro 
assays for bacterial proliferation inhibition, GroEL/ES inhibition (both substrate folding 
and ATPase functions), human cell cytotoxicity, and bacterial resistance towards lead 
analogs. The results from testing analogs in this panel of biochemical and cell-based 
experiments is presented below, with a discussion on SAR and the potential of these 
series as GroEL/ES-targeting antibacterial candidates. 
 
Figure 8 – Structural similarity of 1 to known antibiotics and SAR strategy Comparison of 
the structure of hit GroEL/ES inhibitor 1 with known antibiotics nitroxoline, nifuroxazide, and 
nitrofurantoin. The hydroxyquinoline group (circled in red) is shared between 1 and the Gram-
negative inhibitor nitroxoline. Also, the N-acyl hydrazone core (circled in blue) is shared between 
1 and known antibiotics nifuroxazide and nitrofurantoin. The additional nitrofuran group (circled in 
green) is a component that is unique to nifuroxazide and nitrofurantoin, but not present in 1. 
Analogues of compound 1 were synthesized where the N-acyl hydrazine linker was maintained 
constant, the right-hand R-substructures were varied as indicated, and the left-hand aryl 
substructure consisted of either hydroxyquinoline (mirroring 1 and nitroxoline) or nitrofuran 
(mirroring nifuroxazide and nitrofurantoin). 
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RESULTS AND DISCUSSION 
Development of hydroxyquinoline and nitrofuran compound series 
As discussed in the introduction, I investigated two primary series of compound 1 
analogues in this study: (1) hydroxyquinolines (analogs 1-15) and (2) nitrofurans 
(analogs 16-28 and also including nifuroxazide and nitrofurantoin). A third group of 
analogues (29-42) was also investigated to determine which substructures of the 
hydroxyquinoline and nitrofuran aryls were required for inhibitor potency in the 
respective assays. Analogues were all synthesized through a one-step coupling reaction 
between the respective aryl-aldehydes and hydrazides in DMSO, with HCl as a catalyst 
(Scheme 1). After stirring overnight at room temperature, the final Schiff base products 
were precipitated through the addition of water, and the solids were filtered and dried in 
vacuo. Synthesized analogues were analyzed by RP-HPLC for purity and LC-MS and 
1H-NMR for structural confirmation (complete characterization data can be found in the 
Experimental section). While all compounds were found to be >95% pure using two 
distinct sets of RP-HPLC conditions, for some analogues (e.g. 3, 4, 6, 9, 10, 17, 23), we 
noticed a splitting of peaks in the 1H-NMR spectra. This phenomenon has previously 
been studied and reported as resulting from hindered rotation around the CO-NH bond, 
providing rotational isomers (rotamers).36 Thus, I believe that the purity of these 
compounds is consistent with HPLC results being >95% pure. 
 
Scheme 1 General protocol for synthesizing compound 1 analogs. Reaction mixtures were stirred 
overnight at room temperature, then the Schiff-base products were precipitated with water, 
filtered, and dried in vacuo. 
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Identifying antibacterial efficacy of compound 1 analogues against the ESKAPE 
pathogens and E. coli 
Analogues were initially tested for antibacterial activity against representative 
strains of E. coli and the ESKAPE bacteria (refer to the Experimental section for strain 
and vendor information for the respective bacteria). To determine compound efficacy, 
bacterial proliferation assays were carried out in liquid media culture supplemented with 
physiological concentrations of free calcium and magnesium cations. For these assays, 
initial bacterial cultures (OD600=0.01) were exposed to test compounds in 8-point, 3-fold 
dilution series (100 μM → 46 nM concentration range). After addition of compounds to 
cultures, the plates were sealed with Breathe-Easy membranes and allowed to 
incubate/grow to mid-log phase (OD600~0.4-0.6), whereupon final OD600 readings were 
taken to assess for bacterial growth inhibition. An in-depth protocol for this common set 
of proliferation assays is provided in the Experimental section, and calculated EC50 
values are reported in Table 2A in the Appendix (log-transformed EC50 values with 
standard deviations are presented in Table 2B). A heat map portraying inhibitor 
potencies against the respective bacteria is presented in Figure 9 for easier visualization 
of results, with darker cells representing the most potent analogues, and lighter cells 
least potent inhibitors. 
Results from the bacterial proliferation assays indicated that the hydroxyquinoline 
analogues were largely ineffective against E. coli and the ESKAPE pathogens, as only a 
few weak inhibitors (EC50 values below the 100 µM threshold) were discovered. This 
was a disappointing result as, prior to initiating this study, I hypothesized that the metal-
chelating properties of the hydroxyquinoline substructure might allow these inhibitors to 
act as siderophores that could be actively uptaken into bacteria, thus bypassing the 
potential problems of having to passively diffuse across the impermeable LPS outer 
membrane.37 Despite this setback, I was excited to see that many of the nitrofuran-
16 
based analogs were much more effective at inhibiting bacterial growth. In particular, 16-
20, 22-24, and 26 were moderate to strong inhibitors of the Gram-positive E. faecium 
and S. aureus bacteria. It appeared that analogues with bulkier R-groups were slightly 
less effective than those with smaller R-groups. While antibacterial effects were limited 
against the Gram-negative KAPE bacteria, what stood out was that several analogs with 
small R-groups (16-20) were very potent against E. coli. Compounds 16 and 17 were 
even more potent than nitroxoline, nifuroxazide, and nitrofurantoin, with EC50 values <1 
μM. This was a significant finding, as previous Johnson group studies had failed to 
identify lead analogs with significant efficacies against E. coli. As evidenced by the 
results of compound 39, which has an unsubstituted furan ring, the nitro-group was 
essential for antibacterial effects. This is putatively because nitrofuran antibiotics are 
activated to reactive metabolites by nitroreductases in bacteria, which is discussed in 
greater detail below. Since the Schiff base analogs were largely ineffective against the 
KAPE bacteria, yet the hydroxyquinoline and nitrofuran aldehyde starting materials (40 
and 41, respectively) were potent inhibitors of nearly all the bacteria (excluding P. 
aeruginosa), it was evident that the imine bonds of the N-acyl hydrazine linkers were not 
hydrolyzing to give the starting materials. As a result, inhibitor potencies likely owe to the 
final products. 
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Figure 9 – Heat map of analogue potencies against ESKAPE and E. coli bacteria Shown is a 
heat map displaying relative antibacterial potencies (EC50 values) for analogues tested in all 
bacteria proliferation assays. Cells that are shaded dark blue are most potent, while those that 
are shaded lighter less potent to inactive (>100 μM). Nitrofurans with small R-groups, particularly 
analogues 16-20, are potent against E. faecium and S. aureus (Gram-positive bacteria), as well 
as E. coli (Gram-negative). Associated R-groups for the most potent inhibitors are indicated to the 
right. 
 
 
Evaluating analogues for their ability to inhibit GroEL/ES-mediated refolding of 
substrate polypeptides in vitro. 
Since I found many potent inhibitors of bacterial growth that merited further 
investigation, I next proceeded to evaluate their abilities to inhibit GroEL/ES-mediated 
folding and ATPase functions. All test compounds were first evaluated in standard 
GroEL/ES-mediated refolding assays that employ malate dehydrogenase (MDH) and 
Rhodanese (Rho) as the denatured substrate reporter enzymes (detailed descriptions of 
the assay protocols are presented in the Experimental section, with schematics 
presented in Figure 10). These enzymes are efficiently folded by GroEL/ES in the 
absence of inhibitors, and thus act as reporter enzymes to determine the degree of 
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inhibition against the bacterial chaperone. Inhibition was examined in the presence of 
these two orthogonal substrates in order to support that GroEL/ES inhibitors were on-
target. To further support on-target effects against GroEL/ES, I counter-screened for 
inhibition of the native MDH and Rho enzymatic reporter reactions, where test 
compounds were added after the denatured MDH and Rho substrate enzymes were 
completely refolded by GroEL/ES. Previous Johnson lab efforts have found that these 
series of biochemical assays are highly effective at eliminating false-positives as 
compounds rarely inhibit both reporter enzymes since their enzymatic read-outs are so 
different from one another. Figure 10 presents general schematics for both the 
GroEL/ES-mediated dMDH and dRho refolding assays and the native MDH and Rho 
reporter counter-screens, with IC50 results presented in Table 3A in the Appendix. While 
GroEL and GroES from E. coli were used as surrogates in these assays, I anticipate 
inhibition results will translate to the chaperonin systems of the other ESKAPE bacteria 
owing to their high sequence similarities: 60.2% with E. faecium; 56.8% with S. aureus; 
96.4% with K. pneumonia; 75.5% with A. baumannii; 79.6% with P. aeruginosa; and 
96.2% with E. cloacae. My lab is currently in the process of generating recombinant 
versions of the respective ESKAPE bacteria GroEL and GroES proteins and will report 
on such inhibition results in the future.  
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Figure 10 – GroEL/ES refolding and native assay schematic General schematics for the 
GroEL/ES refolding assays and native reporter enzyme counter-screens. In the GroEL/ES-dMDH 
refolding assay, compounds were added to a solution of GroEL/ES-dMDH, followed by ATP to 
initiate the refolding cycle. EDTA was added after a short incubation time to quench the refolding 
cycle followed by the enzymatic reporter reagents (NADH and ketomalonic acid (KMA)). Refolded 
MDH (i.e. no GroEL/ES inhibition) converts NADH to NAD+, which was followed by monitoring the 
absorbance of NADH at 340 nm. To identify false-positives that inhibited the refolded MDH, 
compounds were added after the EDTA quench step. In the GroEL/ES-dRho refolding assay, 
compounds were added to a solution of GroEL/ES-dMDH, followed by ATP to initiate the 
refolding cycle. After a short incubation time to allow the dRho substrate to be refolded, the 
sodium thiosulfate and potassium cyanide enzymatic reporter reagents were added and 
incubated for 60 minutes. Then, formaldehyde was added to quench the reporter reaction, 
followed by the Fe(NO3)3 developing solution, forming the Fe(SCN)3 complex that was detected 
at λ=460 nm. To identify false-positives that inhibited the refolded Rho, compounds were added 
after the refolding incubation period, but prior to addition of the enzymatic reporter and developing 
reagents. 
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Unfortunately, I found that the nitrofuran analogues were only weak-to-moderate 
GroEL/ES inhibitors despite their being the most potent at inhibiting bacterial growth 
(blue circles in Figure 11A). Conversely, the hydroxyquinoline analogues (yellow circles 
in Figure 11A) were much stronger GroEL/ES inhibitors, although they were largely 
inactive against bacteria. SAR indicated that analogues with larger R-groups were 
generally more potent than those with smaller R-groups (Table 3A), which was a trend 
generally contradictory to inhibitor potencies against bacteria. While the 
hydroxyquinolines were slightly more potent in the GroEL/ES-mediated dRho compared 
to dMDH refolding assays, this was likely because they had the coupled effects of also 
being weak inhibitors of the native Rho reporter reaction; however, no compounds 
inhibited native MDH, supporting on-target effects against GroEL/ES. That analogue 6 
was more potent in the GroEL/ES-dRho refolding assay is an anomaly since it does not 
inhibit the native Rho reporter reaction. Since analogs 29-39, which consist of R-groups 
where various parts of the hydroxyquinoline substructure were pared away, were largely 
inactive in all biochemical assays indicates the necessity for the complete 
hydroxyquinoline moiety for inhibition. 
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Figure 11 – GroEL/ES refolding and native assay results Correlation plots demonstrate E. coli 
GroEL/ES-mediated refolding and native assays, using both MDH and Rho substrates. Single 
data points represent IC50 values for individual analogues. (A) Hydroxyquinolines were potent 
GroEL/ES inhibitors, whereas nitrofurans were weak-to-moderate GroEL/ES inhibitors. The 
majority of hydroxyquinoline inhibitors appeared to be slightly more potent in the GroEL/ES-
mediated dRho assay, as opposed to the dMDH assay (Pearson correlation coefficient for 
inhibiting in both refolding assays is 0.905, p < 0.0001). One analogue, 6, was potent in the dRho 
assay but ineffective in the dMDH assay. (B) While several compounds were found to be weak 
inhibitors in the native Rho counter-screen, none inhibited native MDH, supporting on-target 
effects against GroEL/ES since they were strong inhibitors in the GroEL/ES-dMDH refolding 
assay. 
 
 
 
Evaluating whether or not analogues inhibit GroEL ATPase functions. 
Since ATPase events are common among many biological processes, inhibiting 
GroEL/ES by competitively binding to the ATP sites could prove problematic for being 
able to selectively target the chaperonin system. Thus, I next employed a well-
established GroEL ATPase assay using malachite green to monitor inorganic phosphate 
liberated as ATP gets hydrolyzed by GroEL. Briefly, a solution of GroEL was incubated 
with test compounds (8-point, 3-fold dilution series) and the assay initiated by addition of 
ATP. After incubating for 45 minutes, the ATPase reaction was quenched by the addition 
of EDTA. Malachite green was then added to the assay to bind and detect free 
phosphates in solution, giving off a green colorimetric reaction (absorbance detection at 
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λ=600 nm). If analogues inhibited ATPase activity, then there would be no free 
phosphates for malachite green to bind, leading to a yellow solution color (minimal 
absorbance at 600 nm). The detailed procedure for this assay is presented in the 
Experimental section. As indicated in Figure 12 (and IC50 results in Table 3A in the 
Appendix), none of the analogues from either series inhibited the GroEL by blocking 
ATP hydrolysis. Thus, I believe that these inhibitors bind to sites outside of the ATP 
pockets. The Johnson lab is currently pursuing studies to identify these unknown binding 
sites, which will be reported on in the future. While these results alleviate concerns about 
non-selectively targeting other ATP-dependent proteins (at least as competitive ATP 
inhibitors), I further assessed for off-target effects through a more definitive approach of 
evaluating for cytotoxicity of analogues to human cells, as discussed further below. 
  
Figure 12 – GroEL/ES-dMDH refolding vs. ATPase inhibition Correlation plot demonstrates 
that none of the GroEL/ES inhibitors (hydroxyquinolines or nitrofurans) inhibit the ability of GroEL 
to hydrolyze ATP. 
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Evaluating the effects of the E. coli NfsB type-1 nitroreductase on the ability of 
test compounds to inhibit GroEL/ES 
While in the previous section I discussed how the hydroxyquinolines were shown 
to be potent GroEL/ES inhibitors, whereas nitrofurans were not, this interpretation is 
complicated by the fact that nitrofuran-based compounds act as prodrugs in vivo – they 
require metabolism by bacterial nitroreductases to generate reactive metabolites that are 
associated with their antibacterial effects.38 Because the standard GroEL/ES-mediated 
refolding assays and native substrate reporter counter-screens were conducted without 
nitroreductases present, the nitrofuran analogues were not undergoing bioactivation 
during these tests. This emphasized the need to re-examine analogues in modified 
refolding and native assays that included a nitroreductase enzyme to activate the 
nitrofuran analogs in situ.     
There are two main classifications of nitroreductase enzymes: Nitroreductase I 
(NTR1, oxygen-insensitive) and Nitroreductase II (NTR2, oxygen-sensitive).39 As shown 
in Figure 13, NTR1 functions by performing two-electron reductions on compounds.40  In 
this activation pathway, NTR1 initially undergoes consecutive reductions, converting the 
nitro group to a nitroso group, then the nitroso group to a hydroxylamine intermediate. 
From there, three separate pathways are possible: (1) reduction into an amine 
(putatively inert);41,42  (2) reduction into a nitrenium ion (highly electrophilic and could 
form covalent adducts);41,43-45 and (3) a furan ring-opening event that forms either 
saturated or unsaturated open-chain nitriles (offers potential Michael addition 
interactions with active site residues).41,46 Unlike NTR1, NTR2 operates via one-electron 
reductions and converts the nitrofuran group to a nitro radical anion. 40,45 Since the nitro 
radical anion is unstable, it oxidizes back to the initial nitro group and creates reactive 
oxygen species in the process, which can induce cell death at high concentrations.45   
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Figure 13 – NTR1 and NTR2 bioactivation pathways This is a diagram laying out the various 
pathways of nitrofuran activation that can take place under the influence of NTR1 and NTR2. 
NTR1 operates via 2-electron reductions, which leads to a hydroxylamine intermediate. From 
there, three pathways can take place: (1) further reduction to a potentially inert amine; (2) 
formation of an electrophilic nitrenium ion, which could possibly bind guanine bases in bacterial 
DNA; (3) nitrofuran ring-opening event that might prompt covalent modification of enzyme active 
site residues. NTR2 operates via 1-electron reductions. Because the initial reduction leads to an 
unstable nitro radical anion, it is quickly converted back to the nitro group. In the presence of 
oxygen, this conversion enables the transfer of a free radical to the oxygen molecule. This 
generates superoxide, which is a precursor to ROS generation. 
 
 
 
 
 
 
 
 
The question then became whether to use NTR1 or NTR2 in the modified 
GroEL/ES refolding and native assays. Because NTR2 is pertinent to bicyclic/polycyclic 
nitro drug activation and NTR1 is pertinent to monocyclic nitro drug activation (as seen in 
the nitrofuran analogues), NTR1 was selected.47 As an initial test to see whether or not 
the activated nitrofuran metabolites would be more potent GroEL/ES inhibitors, we 
purchased the E. coli NfsB type 1 nitroreductase (Sigma #N9284) and modified the 
standard GroEL/ES-dMDH refolding and native MDH counter-screens to generate the 
reactive metabolites in situ. Detailed protocols for these experiments are presented in 
the Experimental section, with IC50 results presented in Table 4A in the Appendix, and 
graphically shown in Figure 14. It was exciting to see that in the presence of NfsB, the 
nitrofuran analogues exhibited dramatically increased inhibition of GroEL/ES refolding 
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functions. Since the IC50 values for the hydroxyquinoline (1-15) and other analogs 
without any nitro groups (e.g. 29-42) were nearly identical in the presence and absence 
of NfsB, this supports that increased inhibition was dependent on the nitrofuran moiety 
and not other effects from the overall compound scaffold or NfsB itself.  Furthermore, 
that the activated nitrofurans were still inactive in the native MDH reporter counter-
screen indicates that the increased inhibitor effects were obtained through selectively 
targeting GroEL/ES in the refolding assay. While the degree of potency shift varied 
between the various analogues, eleven shifted to IC50 values of less than or equal to 10 
μM. As a point of comparison, the most potent nitrofuran analogue in the absence of 
NfsB had an IC50=20 μM, with three being completely inactive (IC50 >100 μM). Significant 
potency shifts were observed for the most effective antibacterials (16-20). This shows 
that some of the strongest antibacterial compounds were also strong GroEL/ES 
inhibitors when exposed to a compatible nitroreductase enzyme. While activated 
nifuroxazide and nitrofurantoin were only moderate GroEL/ES inhibitors in this assay, 
this is perhaps not surprising as they are reported in the literature to be preferentially 
activated by the other E. coli type 1 nitroreductase, NfsA. As the different nitrofuran 
analogs would be expected to exhibit varying SAR for activation by NfsA and NfsB, it will 
be important to test inhibitors in the presence of both to gain a more complete picture of 
how inhibitors could be function in bacteria. Because of the limitations of employing only 
NfsB and evaluating such a small number of nitrofuran analogues, it is difficult to 
ascertain correlations between the nitrofurans inhibiting in the in situ NfsB-GroEL/ES-
dMDH refolding assay and inhibition of bacterial growth (Figure 15A-C). My lab is now 
in the process of cloning and expressing the E. coli NfsA and NfsB nitroreductase 
variants and developing an expanded panel of nitrofuran-based analogs. Furthermore, 
investigating the nitroreductases of the various ESKAPE bacteria could provide a 
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stronger rationale for why these compounds are largely inactive against the KAPE 
Gram-negative strains. Associated findings will be reported in future works. 
 
Figure 14 – Chaperone refolding and native MDH enzymatic activity with and without NfsB 
Correlation plots indicate GroEL/ES inhibition potency shifts in the presence of NfsB. Addition of 
NfsB causes only the nitrofuran analogues to gain in potency against GroEL/ES.                                                                                                                               
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 – GroEL/ES-dMDH refolding vs. bacterial growth inhibition Correlation plots to 
identify potential on-target effects targeting GroEL/ES in E. faecium (A), S. aureus (B), and E. coli 
(C). While increasing inhibition by the nitrofurans in the in situ NfsB-GroEL/ES-dMDH refolding 
assay may provide more effective inhibition of S. aureus growth (an potentially E. faecium), more 
thorough studies will need to be conducted, testing a larger number of nitrofuran analogs in the 
presence of both NfsA and NfsB, to gain a clearer picture of whether or not compounds may be 
functioning on-target against GroEL/ES in bacteria. 
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Evaluating analogues for cytotoxicity to human colon and small intestinal cells 
While in previous studies, I (as well as previous members) have employed 
counter-screening with the human HSP60/10 chaperonin system, accumulating results 
continually reinforce that inhibiting HSP60/10 in vitro is a poor indicator of potential off-
target toxicity to human cells.28-32 This is highlighted by the fact that we have identified 
many known drugs and natural products that are potent HSP60/10 inhibitors in vitro, a 
primary example of which is suramin, which has been safely used for over 100 years as 
a first-line treatment for Trypanosoma brucei infections.29,48 In addition, as now identified 
in this study, bioactivation of nitrofuran analogues (and the drug, nifuroxazide) by 
nitroreductase enzymes greatly increases the degree of inhibition against GroEL/ES 
refolding activity. This further complicates testing against human HSP60/10, since 
human cells do not contain nitroreductases. Therefore, I feel the most appropriate initial 
assessment of potential in vivo toxicity is to test compounds for cytotoxicity to human 
cells in cell culture. Thus, to screen for potential cytotoxic effects, analogues were tested 
in two Alamar Blue-based cell viability assays using human FHC colon cells and FHs 74 
Int small intestinal cells. Briefly, I first grew cells to ~90% confluency, then sub-cultured 
1,500 cells per well in the absence of test compounds for 24 h. Test compounds were 
then added and the cultures were incubated for an additional 48 h, whereupon the 
Alamar Blue reporter reagents were added and well fluorescence was monitored over 
time. Alamar Blue contains resazurin (non-fluorescent), which is reduced to resorufin 
(highly fluorescent) in the presence of healthy, viable cells. A detailed protocol is 
presented in the Experimental section, with cell cytotoxicity CC50 values presented in 
Table 5A in the Appendix. As observed in Figure 16, lead nitrofuran inhibitors were able 
to selectively kill E. faecium, S. aureus, and E. coli bacteria with low-to-no cytotoxicity to 
human cells (representative results are shown for human FHC colon cells, but FHs 74 
Int results are similar). Intriguingly, the nitrofuran analogues were typically less toxic than 
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their hydroxyquinoline counterparts, putatively because they would need to be 
metabolized to their active intermediates, yet human cells do not harbor nitroreductases. 
 
 
Figure 16 – FHC vs. FHS 74 Int cytotoxicity Correlation plots demonstrate differences between 
compound cytotoxicity to human FHC colon cells and inhibition of the proliferation of E. faecium 
(A), S. aureus (B), and E. coli (C). It is clear that nitrofuran analogues are selective for inhibiting 
bacteria over FHC colon cells (results for cytotoxicity to human FHs 74 Int small intestine cells are 
similar, with CC50 values reported in Table 5A in the Appendix). 
 
 
Investigating the ability of E. coli to gain resistance to 17, nifuroxazide, and 
nitrofurantoin 
As I discovered several nitrofuran-based analogs that selectively inhibited the 
growth of E. faecium, S. aureus, and E. coli with minimal toxicity to human cells, I next 
wanted to explore how easy it would be for bacteria to generate resistance to a lead 
candidate. I examined the ability of E. coli to generate resistance to 17 (with nifuroxazide 
and nitrofurantoin as controls), since resistance to nitrofuran-based antibiotics has been 
well-characterized in this bacterium. While 17, nifuroxazide, and nitrofurantoin were all 
potent inhibitors of E. coli proliferation, 17 was the most potent at inhibiting GroEL/ES in 
the presence of NfsB, and thus may exhibit greater on-target effects in bacteria. 
However, there are limitations in the above experiments, as they do not employ the NfsA 
nitroreductase. To determine if there might be any difference in the ability of E. coli to 
generate resistance to these three compounds with such distinct bioactivity profiles, I 
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employed a 12 day resistance assay as was previously reported with the biphenylamide 
compound 44 analogues.32 A detailed protocol of this assay is presented in the 
Experimental section. Briefly, a dilute culture of E. coli (OD600=0.01) was grown in the 
presence of inhibitors (tested in dose-response in duplicates) for 24 h, then EC50 results 
were determined from the OD600 readings of the wells. Over the course of 12 days, I 
sequentially sub-cultured bacteria from the respective wells with the highest 
concentration of inhibitors where bacteria grew to an OD600 >0.2, monitoring for 
increases in EC50 values over time.  
As shown in Figure 17, nifuroxazide and nitrofurantoin were initially more potent 
than 17, putatively owing to their preferential activation by NfsA. However, E. coli quickly 
developed intermediate resistance (within 3-5 days) such that all three inhibitors were 
nearly equipotent in the 20-40 μM range. Literature precedence shows that resistance to 
nitrofuran antibiotics typically occurs first through mutations affecting NfsA.49 That EC50 
values generally plateaued in the 20-40 μM range is consistent with previous reports that 
NfsB is still able to metabolize the nitrofuran moieties, allowing them to maintain efficacy; 
however it may further indicate that it is more difficult for bacteria to generate resistance 
through mutating this second nitroreductase. Thus, inhibitors that are preferentially 
activated by NfsB, as may be the case for 17, might be more effective drug candidates 
with respect to combatting the emergence of drug resistant strains, although this 
remains to be shown. I note, though, that EC50 values continued to slowly increase over 
time for all three compounds, with a particular jump in resistance seen for replicate 2 of 
nitrofurantoin.   
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Figure 17 – E. coli resistance generation against lead antibacterials Evaluating the ability of 
E. coli to generate resistance to nifuroxazide (A), nitrofurantoin (B), and  compound 17 (C) over 
time. The time-course plots show the change in EC50 values for each compound over the 12-day 
serial passage resistance assay (compound tested in duplicates, as indicated by the white 
triangles and black diamonds). 
 
I next confirmed that the resistance generated by the replicate E. coli strains was 
irreversible (i.e. putatively through permanent mutations of NfsA and NfsB, as previously 
reported) as opposed to transient means (i.e. by up-regulating efflux pumps). To 
accomplish this, I sub-cultured single colonies obtained from the replicate samples 
where the bacteria exhibited the greatest degree of resistance to test compounds (day 
12 samples for all compound replicates, except replicate 2 for nitrofurantoin, which was 
taken at day 10), for 4 x 12 h serial passages in fresh media without any test compounds 
present. I then performed another 24 h follow-up proliferation assay to determine EC50 
values. As seen in Figure 18, the bacterial strains were still resistant to each of the 
respective inhibitors they were generated from, supporting that resistance was 
permanent. Previous studies have extensively characterized mutations affecting NfsA 
and NfsB that E. coli acquire to generate resistance mechanisms against nitrofuran 
antibiotics, and thus genotyping was not performed to further characterize the specific 
resistance mechanisms for these strains, as they are likely the same.49 
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Figure 18 – E. coli permanent resistance against lead antibacterials  Dose-response curves 
for nifuroxazide (A), nitrofurantoin (B), and compound 17 (C) for susceptible parent E. coli (shown 
in blue), the maximally-resistant strains developed to the respective test compounds (shown in 
orange), and follow-up proliferation assays for resistant strains tested after 4 x 12 h serial 
passaging in the absence of test compounds to account for possible reversible inhibition 
mechanisms (shown in purple).   
 
As nifuroxazide, nitrofurantoin, and 17 displayed different inhibition and 
resistance profiles with one another, I was curious to determine if the respective 
resistant strains were cross-resistant with each of the other inhibitors. Intriguingly, while 
the replicate strains that were initially resistant to nifuroxazide were cross-resistant to 
both nitrofurantoin and 17 (Figure 19A), the nitrofurantoin-resistant strains were still 
sensitive to nifuroxazide and 17 (Figure 19B), and the 17-resistant strains were 
susceptible to nifuroxazide, but not nitrofurantoin (Figure 19C). Thus, it is evident that 
strains that have generated resistance to one analogue are not necessarily cross-
resistant to other analogues. Further studies are warranted to see if combination therapy 
with 2 or more inhibitor analogues might be synergistic and prevent or prolong the 
emergence of resistant strains. 
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Figure 19 – Evaluation of E. coli cross-resistance against lead antibacterials Evaluation of 
cross-resistance between the respective resistant E. coli strains with nifuroxazide, nitrofurantoin, 
and 17. The three panels show dose-response curves for the three inhibitors tested against 
strains where resistance was initially generated to nifuroxazide (A), nitrofurantoin (B), and 17 (C). 
Results indicate that resistance generated to one inhibitor is not necessarily cross-resistant to the 
other inhibitors, potentially indicating different mechanisms of activation and/or targets. 
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CONCLUSIONS 
In a previous high-throughput screen, hit compound 1 was identified as a 
moderate GroEL/ES inhibitor with weak activity against two Gram-negative bacteria, K. 
pneumoniae and A. baumannii. The structure of this hit inhibitor resembles known 
antibiotics nitroxoline (i.e. shared hydroxyquinoline moiety) and nifuroxazide / 
nitrofurantoin (i.e. shared N-acyl hydrazone core). The main difference between 1 and 
nifuroxazide and nitrofurantoin is that the latter two possess a nitrofuran in place of 
hydroxyquinoline group. With the goal of increasing inhibitor potency against GroEL/ES 
and E. coli and the ESKAPE bacteria, while reducing cytotoxicity to human cells, I 
developed two primary series of hydroxyquinoline and nitrofuran-bearing analogues. 
These analogues possessed R-groups on the distal ends of the scaffolds of varying 
sizes and chemical compositions to identify SAR profiles.  
Results from bacterial proliferation testing demonstrated that the nitrofurans with 
small R-groups (16-20) were potent inhibitors of E. faecium, S. aureus, and E. coli (with 
maximum efficacy against E. coli). Initially, only the hydroxyquinolines were found to be 
potent GroEL/ES inhibitors in traditional GroEL/ES-mediated substrate refolding assays, 
whereas nitrofurans were only weak-to-moderate inhibitors. However, subsequent 
testing in the presence of the E. coli NfsB nitroreductase indicated that the nitrofurans 
act as prodrugs and their reactive metabolites can be potent GroEL/ES inhibitors. Lead 
nitrofuran antibacterial analogs also exhibited minimal cytotoxicity to human FHC colon 
and FHs 74 Int small intestinal cells. When evaluating E. coli resistance generation 
against lead antibacterials (17, nifuroxazide, and nitrofurantoin), it was evident that all 
three compounds experienced resistance, albeit to varying degrees. Nifuroxazide and 
nitrofurantoin were shown to be most effective initially, however, they were found to 
generate resistance in E. coli more rapidly than compound 17 did. This could potentially 
be attributed to the two drugs being more reliant on NfsA for bioactivation than 17 (as 
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previous literature has pointed to NfsA mutations being a primary cause of early 
nitrofuran drug resistance), or because 17 is a more potent inhibitor of GroEL/ES. 
Resistance to each compound was revealed to be permanent in nature, as opposed to 
transient (i.e. up-regulation of efflux pumps). Upon further examination, strains that were 
able to generate resistance against one of the lead antibacterials were not necessarily 
cross-resistant to the other inhibitors, which could indicate diverging mechanisms of 
activation and/or targets. This may indicate that combination therapy with structurally 
distinct analogs could prove synergistic and delay the onset of bacterial resistance.  
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EXPERIMENTAL  
General synthetic methods 
Unless otherwise stated, all chemicals were purchased from commercial 
suppliers and used without further purification.  Reaction progress was monitored by 
thin-layer chromatography on silica gel 60 F254 coated glass plates (EM Sciences).  
Flash chromatography was performed using a Biotage Isolera One flash 
chromatography system and eluting through Biotage KP-Sil Zip or Snap silica gel 
columns for normal-phase separations (hexanes:EtOAc gradients), or Snap KP-C18-HS 
columns for reverse-phase separations (H2O:MeOH gradients).  Reverse-phase high-
performance liquid chromatography (RP-HPLC) was performed using a Waters 1525 
binary pump, 2489 tunable UV/Vis detector (254 and 280 nm detection), and 2707 
autosampler.  For preparatory HPLC purification, samples were chromatographically 
separated using a Waters XSelect CSH C18 OBD prep column (part number 
186005422, 130 Å pore size, 5 µm particle size, 19x150 mm), eluting with a H2O:CH3CN 
gradient solvent system.  Linear gradients were run from either 100:0, 80:20, or 60:40 
A:B to 0:100 A:B (A = 95:5 H2O:CH3CN, 0.05% TFA; B = 5:95 H2O:CH3CN, 0.05% TFA.  
Products from normal-phase separations were concentrated directly, and reverse-phase 
separations were concentrated, diluted with H2O, frozen, and lyophilized.  For primary 
compound purity analyses (HPLC-1), samples were chromatographically separated 
using a Waters XSelect CSH C18 column (part number 186005282, 130 Å pore size, 5 
µm particle size, 3.0x150 mm), eluting with the above H2O:CH3CN gradient solvent 
systems.  For secondary purity analyses (HPLC-2) of final test compounds, samples 
were chromatographically separated using a Waters XBridge C18 column (part number 
186003132, 130 Å pore size, 5.0 µm particle size, 3.0x100 mm), eluting with a 
H2O:MeOH gradient solvent system.  Linear gradients were run from either 100:0, 80:20, 
60:40, or 20:80 A:B to 0:100 A:B (A = 95:5 H2O:MeOH, 0.05% TFA; B = 5:95 
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H2O:MeOH, 0.05% TFA).  Test compounds were found to be >95% in purity from both 
RP-HPLC analyses.  Mass spectrometry data were collected using either Agilent LC 
1200-MS 6130 or Agilent LC 1290-MS 6545 Q-TOF analytical LC-MS instruments at the 
IU Chemical Genomics Core Facility (CGCF).  1H-NMR spectra were recorded on a 
Bruker 300 MHz spectrometer at the IU CGCF.  Chemical shifts are reported in parts per 
million and calibrated to the d6-DMSO solvent peaks at 2.50 ppm.       
 .......................................................................................................................................... 
1-(((8-hydroxyquinolin-5-yl)methylene)amino)imidazolidine-2,4-dione (2).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.30 (s, 1H), 9.66 (dd, J = 8.7, 1.3 Hz, 1H), 8.99 (dd, J 
= 4.4, 1.4 Hz, 1H), 8.21 (s, 1H), 7.92 (d, J = 8.2 Hz, 1H), 7.86 (dd, J = 8.8, 4.5 Hz, 1H), 
7.27 (d, J = 8.1 Hz, 1H), 4.46 (s, 2H); MS (ESI) C13H11N4O3 [MH]+ m/z expected = 271.1, 
observed = 271.0. HPLC-1 = 98%, HPLC-2 = 98%. 
 .......................................................................................................................................... 
N'-((8-hydroxyquinolin-5-yl)methylene)thiophene-2-carbohydrazide (3).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.86 (s, 0.6H), 11.74 (s, 0.3H), 10.46 (br s, 0.8H), 9.57 
(d, J = 8.4 Hz, 0.6H), 8.94 (dd, J = 4.1, 1.4 Hz, 1.3H), 8.79 (s, 0.7H), 8.71 (s, 0.3H), 
7.65-8.11 (m, 4H), 7.12-7.31 (m, 2H) – Putatively mixture of ~2:1 rotamers; MS (ESI) 
C15H12N3O2S [MH]+ m/z expected = 298.1, observed = 298.0; HPLC-1 = 99%;  
 .......................................................................................................................................... 
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5-chloro-N'-((8-hydroxyquinolin-5-yl)methylene)thiophene-2-carbohydrazide (4).   
 
1H-NMR (300 MHz, d6-DMSO) δ 9.55 (d, J = 8.1 Hz, 0.5H), 8.93 (dd, J = 4.0, 1.2 Hz, 
1H), 8.84 (d, J = 8.6 Hz, 0.5H), 8.74 (d, J = 9.4 Hz, 1H), 8.02 (d, J = 8.1 Hz, 0.5H), 7.89 
(d, J = 4.1 Hz, 0.5H), 7.76-7.85 (m, 0.9H), 7.66-7.75 (m, 1.1H), 7.12-7.32 (m, 2H) – 
Putatively mixture of ~1:1 rotamers; MS (ESI) C15H11ClN3O2S [MH]+ m/z expected = 
332.1, observed = 332.0; HPLC-1 = 97%; HPLC-2 = 98%. 
 .......................................................................................................................................... 
N'-((8-hydroxyquinolin-5-yl)methylene)benzohydrazide (5).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.84 (s, 1H), 9.61 (dd, J = 8.7, 1.4 Hz, 1H), 8.94 (dd, J 
= 4.1, 1.4 Hz, 1H), 8.83 (s, 1H), 7.90-8.00 (m, 2H), 7.78 (d, J = 8.2 Hz, 1H), 7.74 (dd, J = 
8.8, 4.2 Hz, 1H), 7.50-7.65 (m, 3H), 7.17 (d, J = 8.1 Hz, 1H); MS (ESI) C17H14N3O2 [MH]+ 
m/z expected = 292.1, observed = 292.1; HPLC-1 = 98%; HPLC-2 = 99%. 
 .......................................................................................................................................... 
N'-((8-hydroxyquinolin-5-yl)methylene)isonicotinohydrazide (6).   
  
1H-NMR (300 MHz, d6-DMSO) δ 12.14 (s, 0.8H), 12.08 (s, 0.1H), 9.74 (dd, J = 8.7, 1.4 
Hz, 0.8H), 9.00 (dd, J = 4.3, 1.5 Hz, 1H), 8.82-8.90 (m, 2.8H), 8.48 (s, 0.1H), 7.90-7.98 
(m, 1.8H), 7.77-7.90 (m, 1.9H), 7.69-7.74 (m, 0.1H), 7.49-7.57 (m, 0.2H), 7.25 (d, J = 8.1 
Hz, 0.9H), 7.13-7.20 (m, 0.1H) – Putatively mixture of ~9:1 rotamers; MS (ESI) 
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C16H13N4O2 [MH]+ m/z expected = 293.1, observed = 293.1; HPLC-1 = 98%, HPLC-2 = 
>99%. 
 .......................................................................................................................................... 
4-hydroxy-N'-((8-hydroxyquinolin-5-yl)methylene)benzohydrazide (7).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.61 (s, 1H), 10.22 (br s, 1H), 9.60 (d, J = 8.5 Hz, 1H), 
8.92 (d, J = 2.9 Hz, 1H), 8.80 (s, 1H), 7.79-7.91 (m, 2H), 7.65-7.78 (m, 2H), 7.14 (d, J = 
8.0 Hz, 1H), 6.82-6.93 (m, 2H); MS (ESI) C17H14N3O3 [MH]+ m/z expected = 308.1, 
observed = 308.0; HPLC-1 = 98%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
N'-((8-hydroxyquinolin-5-yl)methylene)-4-methoxybenzohydrazide (1).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.70 (s, 1H), 10.44 (br s, 1H), 9.61 (d, J = 8.6 Hz, 1H), 
8.94 (d, J = 2.8 Hz, 1H), 8.81 (s, 1H), 7.90-8.01 (m, 2H), 7.68-7.82 (m, 2H), 7.17 (d, J = 
8.1 Hz, 1H), 7.04-7.13 (m, 2H), 3.85 (s, 3H); MS (ESI) C18H16N3O3 [MH]+ m/z expected = 
322.1, observed = 322.1; HPLC-1 = 99%; HPLC-2 = 99%. 
 .......................................................................................................................................... 
4-(dimethylamino)-N'-((8-hydroxyquinolin-5-yl)methylene)benzohydrazide (8).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.52 (s, 1H), 10.36 (br s, 1H), 9.60 (d, J = 8.0 Hz, 1H), 
8.93 (dd, J = 4.1, 1.6 Hz, 1H), 8.80 (s, 1H), 7.81-7.91 (m, 2H), 7.67-7.78 (m, 2H), 7.16 
39 
(d, J = 8.0 Hz, 1H), 6.72-6.82 (m, 2H), 3.00 (s, 6H); MS (ESI) C19H19N4O2 [MH]+ m/z 
expected = 335.2, observed = 335.1; HPLC-1 = >99%; HPLC-2 = 98%. 
 .......................................................................................................................................... 
N'-((8-hydroxyquinolin-5-yl)methylene)-1-naphthohydrazide (9).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.99 (s, 0.3H), 11.97 (s, 0.6H), 10.45 (br s, 0.9H), 9.66 
(dd, J = 8.7, 1.5 Hz, 0.7H), 8.96 (dd, J = 4.1, 1.6 Hz, 0.7H), 8.72 (s, 0.7H), 8.64-8.69 (m, 
0.3H), 8.23-8.35 (m, 1.0H), 7.99-8.16 (m, 2.3H), 7.87-7.93 (m, 0.3H), 7.73-7.83 (m, 
2.1H), 7.49-7.68 (m, 3.4H), 7.42-7.49 (m, 0.3H), 7.18 (d, J = 8.1 Hz, 0.7H), 6.96-7.03 (m, 
0.3H), 6.75-6.84 (m, 0.3H) – Putatively mixture of ~7:3 rotamers; MS (ESI) C21H10N3O2 
[MH]+ m/z expected = 342.1, observed = 342.1; HPLC-1 = >99%; HPLC-2 = 99%. 
 .......................................................................................................................................... 
N'-((8-hydroxyquinolin-5-yl)methylene)-2-phenoxybenzohydrazide (10).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.73 (s, 0.4H), 11.70 (s, 0.6H), 10.39 (br s, 0.8H), 9.57 
(dd, J = 8.7, 1.5 Hz, 0.6H), 8.92 (dd, J = 4.1, 1.5 Hz, 0.6H), 8.78-8.89 (m, 0.8H), 8.65 (s, 
0.6H), 8.31 (s, 0.4H), 7.66-7.78 (m, 1.8H), 7.47-7.58 (m, 1.7H), 7.35-7.45 (m, 1.3H), 
7.20-7.34 (m, 1.4H), 7.10-7.19 (m, 2H), 7.03-7.10 (m, 1.6H), 6.93-7.03 (m, 1.4H), 6.82-
6.89 (m, 0.8H) – Putatively mixture of ~3:2 rotamers; MS (ESI) C23H18N3O3 [MH]+ m/z 
expected = 384.1, observed = 384.2; HPLC-1 = >99%; HPLC-2 = 99%. 
 .......................................................................................................................................... 
  
40 
N'-((8-hydroxyquinolin-5-yl)methylene)-3-phenoxybenzohydrazide (11).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.83 (s, 1H), 10.46 (br s, 1H), 9.59 (dd, J = 8.7, 1.4 
Hz, 1H), 8.94 (dd, J = 4.1, 1.5 Hz, 1H), 8.81 (s, 1H), 7.68-7.82 (m, 3H), 7.53-7.64 (m, 
2H), 7.39-7.50 (m, 2H), 7.13-7.28 (m, 3H), 7.03-7.13 (m, 2H); MS (ESI) C23H18N3O3 
[MH]+ m/z expected = 384.1, observed = 384.1; HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
N,N-diethyl-3-(2-((8-hydroxyquinolin-5-yl)methylene)hydrazine-1-
carbonyl)benzenesulfonamide (12).   
 
1H-NMR (300 MHz, d6-DMSO) δ 12.06 (s, 1H), 10.50 (br s, 1H), 9.62 (dd, J = 8.7, 1.5 
Hz, 1H), 8.95 (dd, J = 4.0, 1.5 Hz, 1H), 8.85 (s, 1H), 8.36 (s, 1H), 8.24 (d, J = 7.8 Hz, 
1H), 8.02 (d, J = 8.0 Hz, 1H), 7.71-7.84 (m, 3H), 7.18 (d, J = 8.0 Hz, 1H), 3.22 (q J = 7.1 
Hz, 4H), 1.06 (t, J = 7.1 Hz, 6H); MS (ESI) C21H23N4O4S [MH]+ m/z expected = 427.1, 
observed = 427.2; HPLC-1 = 99%; HPLC-2 = 99%. 
 .......................................................................................................................................... 
N-(4-(2-((8-hydroxyquinolin-5-yl)methylene)hydrazine-1-
carbonyl)phenyl)thiophene-2-sulfonamide (13).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.71 (s, 1H), 10.90 (s, 1H), 10.44 (br s, 1H), 9.58 (d, J 
= 8.7 Hz, 1H), 8.93 (d, J = 2.7 Hz, 1H), 8.77 (s, 1H), 7.94 (dd, J = 5.0, 1.3 Hz, 1H), 7.81-
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7.91 (m, 2H), 7.69-7.81 (m, 2H), 7.67 (dd, J = 3.7, 1.3 Hz, 1H), 7.23-7.35 (m, 2H), 7.08-
7.20 (m, 2H); MS (ESI) C21H15N4O4S2 [M-H]- m/z expected = 451.1, observed = 451.0; 
HPLC-1 = 99%; HPLC-2 = 99%. 
 .......................................................................................................................................... 
4-bromo-N-(4-(2-((8-hydroxyquinolin-5-yl)methylene)hydrazine-1-
carbonyl)phenyl)benzenesulfonamide (14).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.71 (s, 1H), 10.86 (s, 1H), 10.44 (br s, 1H), 9.57 (d, J 
= 8.6 Hz, 1H), 8.93 (d, J = 2.7 Hz, 1H), 8.78 (s, 1H), 7.66-7.91 (m, 8H), 7.23 (d, J = 8.6 
Hz, 2H), 7.09-7.18 (m, 1H), 8.96 (s, 1H); MS (ESI) C23H16BrN4O4S [M-H]- m/z expected = 
523.0, observed = 522.9; HPLC-1 = 99%; HPLC-2 = 99%. 
 .......................................................................................................................................... 
4-ethoxy-N-(4-(2-((8-hydroxyquinolin-5-yl)methylene)hydrazine-1-
carbonyl)phenyl)benzenesulfonamide (15).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.67 (s, 1H), 10.63 (s, 1H), 10.43 (br s, 1H), 9.57 (d, J 
= 7.8 Hz, 1H), 8.93 (d, J = 2.8 Hz, 1H), 8.76 (s, 1H), 7.67-7.86 (m, 6H), 7.22 (d, J = 8.8 
Hz, 2H), 7.15 (d, J = 8.0 Hz, 1H), 7.06 (d, J = 8.9 Hz, 2H), 4.06 (q, J = 6.9 Hz, 2H), 1.30 
(t, J = 6.9 Hz, 3H); MS (ESI) C25H21N4O5S [M-H]- m/z expected = 489.1, observed = 
489.0; HPLC-1 = 98%; HPLC-2 = 98%. 
 .......................................................................................................................................... 
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N'-((5-nitrofuran-2-yl)methylene)thiophene-2-carbohydrazide (16).   
 
1H-NMR (300 MHz, d6-DMSO) δ 12.26 (s, 1H), 8.35 (br s, 1H), 7.96 (br s, 2H), 7.81 (d, J 
= 4.0 Hz, 1H), 7.28 (d, J = 4.0 Hz, 1H), 7.24 (dd, J = 4.9, 3.9 Hz, 1H); MS (ESI) 
C10H8N3O3S [MH]+ m/z expected = 266.0, observed = 266.1; HPLC-1 = 98%; HPLC-2 = 
98%. 
 .......................................................................................................................................... 
5-chloro-N'-((5-nitrofuran-2-yl)methylene)thiophene-2-carbohydrazide (17).   
 
1H-NMR (300 MHz, d6-DMSO) δ 12.38 (s, 1H), 8.34 (br s, 0.3H), 8.03 (br s, 0.7H), 7.89 
(br s, 0.7H), 7.80 (d, J = 3.9 Hz, 1.3H), 7.24-7.33 (m, 2.2H) – Putatively mixture of ~2:1 
rotamers; MS (ESI) C10H7N3O4S [MH]+ m/z expected = 300.0, observed = 300.0; HPLC-1 
= 98%; HPLC-2 = 98%. 
 .......................................................................................................................................... 
N'-((5-nitrofuran-2-yl)methylene)benzohydrazide (18).   
 
1H-NMR (300 MHz, d6-DMSO) δ 12.25 (s, 1H), 8.40 (br s, 1H), 7.91 (d, J = 7.2 Hz, 2H), 
7.80 (d, J = 3.9 Hz, 1H), 7.59-7.67 (m, 1H), 7.50-7.59 (m, 2H), 7.28 (d, J = 3.6 Hz, 1H); 
MS (ESI) C12H10N3O4 [MH]+ m/z expected = 260.0, observed = 260.1; HPLC-1 = >99%; 
HPLC-2 = 98%. 
 .......................................................................................................................................... 
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N'-((5-nitrofuran-2-yl)methylene)isonicotinohydrazide (19).   
 
1H-NMR (300 MHz, d6-DMSO) δ 12.44 (s, 1H), 8.81 (d, J = 5.6 Hz, 2H), 8.41 (s, 1H), 
7.75-7.89 (m, 3H), 7.33 (d, J = 3.8 Hz, 1H); MS (ESI) C11H9N4O4 [MH]+ m/z expected = 
261.1, observed = 261.1; HPLC-1 = 99%; HPLC-2 = 99%. 
 .......................................................................................................................................... 
4-methoxy-N'-((5-nitrofuran-2-yl)methylene)benzohydrazide (20).   
 
1H-NMR (300 MHz, d6-DMSO) δ 12.12 (s, 1H), 8.39 (br s, 1H), 7.88-7.96 (m, 2H), 7.80 
(d, J = 4.0 Hz, 1H), 7.26 (d, J = 3.9 Hz, 1H), 7.05-7.12 (m, 2H), 3.84 (s, 3H); MS (ESI) 
C13H10N3O5 [M-H]- m/z expected = 288.1, observed = 288.0; HPLC-1 = >99%; HPLC-2 = 
>99%. 
 .......................................................................................................................................... 
4-(dimethylamino)-N'-((5-nitrofuran-2-yl)methylene)benzohydrazide (21).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.95 (s, 1H), 8.38 (s, 1H), 7.77-7.85 (m, 3H), 7.22 (d, J 
= 3.9 Hz, 1H), 6.73-6.81 (m, 2H), 3.01 (s, 6H); MS (ESI) C14H15N4O4 [MH]+ m/z expected 
= 303.1, observed = 303.1; HPLC-1 = >99%; HPLC-2 = 99%. 
 .......................................................................................................................................... 
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N'-((5-nitrofuran-2-yl)methylene)-1-naphthohydrazide (22).   
 
1H-NMR (300 MHz, d6-DMSO) δ 12.26 (s, 1H), 8.30 (s, 1H), 8.18-8.25 (m, 1H), 8.13 (d, J 
= 8.2 Hz, 1H), 7.99-8.08 (m, 1H), 7.76-7.86 (m, 2H), 7.57-7.67 (m, 3H), 7.30 (d, J = 3.9 
Hz, 1H); MS (ESI) C16H12N3O4 [M-H]- m/z expected = 310.1, observed = 310.0; HPLC-1 
= >99%; HPLC-2 = 98%. 
 .......................................................................................................................................... 
N'-((5-nitrofuran-2-yl)methylene)-2-phenoxybenzohydrazide (23).   
 
1H-NMR (300 MHz, d6-DMSO) δ 12.17 (s, 1H), 8.26 (s, 0.7H), 7.92 (s, 0.3H), 7.78 (d, J = 
3.8 Hz, 0.7H), 7.70-7.75 (m, 0.4H), 7.67 (d, J = 7.3 Hz, 0.7H), 7.34-7.58 (m, 2.9H), 6.94-
7.33 (m, 7.0H), 6.893-6.91 (m, 0.4H) – Putatively mixture of ~2:1 rotamers; MS (ESI) 
C18H14N3O5 [MH]+ m/z expected = 352.1, observed = 352.1; HPLC-1 = >99%; HPLC-2 = 
98%. 
 .......................................................................................................................................... 
N'-((5-nitrofuran-2-yl)methylene)-3-phenoxybenzohydrazide (24).   
 
1H-NMR (300 MHz, d6-DMSO) δ 12.25 (s, 1H), 8.39 (s, 1H), 7.80 (d, J = 3.9 Hz, 1H), 
7.70 (d, J = 7.6 Hz, 1H), 7.51-7.61 (m, 2H), 7.38-7.48 (m, 2H), 7.23-7.32 (m, 2H), 7.15-
7.23 (m, 1H), 7.04-7.12 (m, 2H); MS (ESI) C18H14N3O5 [MH]+ m/z expected = 352.1, 
observed = 352.1; HPLC-1 = >99%; HPLC-2 = 98%. 
 .......................................................................................................................................... 
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N,N-diethyl-3-(2-((5-nitrofuran-2-yl)methylene)hydrazine-1-
carbonyl)benzenesulfonamide (25).   
 
1H-NMR (300 MHz, d6-DMSO) δ 12.45 (s, 1H), 8.43 (s, 1H), 8.31 (s, 1H), 8.20 (d, J = 7.2 
Hz, 1H), 8.03 (d, J = 7.7 Hz, 1H), 7.74-7.85 (m, 2H), 7.31 (d, J = 3.4 Hz, 1H), 3.20 (q, J = 
7.1 Hz, 4H), 1.05 (t, J = 7.1 Hz, 6H); MS (ESI) C16H19N4O6S [MH]+ m/z expected = 395.1, 
observed = 395.1; HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
N-(4-(2-((5-nitrofuran-2-yl)methylene)hydrazine-1-carbonyl)phenyl)thiophene-2-
sulfonamide (26).   
 
1H-NMR (300 MHz, d6-DMSO) δ 12.06 (s, 1H), 10.87 (s, 1H), 8.27 (s, 1H), 7.85 (dd, J = 
5.0, 1.4 Hz, 1H), 7.69-7.79 (m, 3H), 7.58 (dd, J = 3.8, 1.4 Hz, 1H), 7.15-7.25 (m, 3H), 
7.06 (dd, J = 4.9, 3.8 Hz, 1H); MS (ESI) C16H13N4O6S2 [MH]+ m/z expected = 421.0, 
observed = 421.1; HPLC-1 = 98%; HPLC-2 = 99%. 
 .......................................................................................................................................... 
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4-bromo-N-(4-(2-((5-nitrofuran-2-yl)methylene)hydrazine-1-
carbonyl)phenyl)benzenesulfonamide (27).   
 
1H-NMR (300 MHz, d6-DMSO) δ 12.11 (s, 1H), 10.89 (s, 1H), 8.34 (s, 1H), 7.70-7.87 (m, 
7H), 7.18-7.31 (m, 3H); MS (ESI) C18H14BrN4O6S [MH]+ m/z expected = 495.0, observed 
= 494.9; HPLC-1 = 98%; HPLC-2 = 97%. 
 .......................................................................................................................................... 
4-ethoxy-N-(4-(2-((5-nitrofuran-2-yl)methylene)hydrazine-1-
carbonyl)phenyl)benzenesulfonamide (28).   
 
1H-NMR (300 MHz, d6-DMSO) δ 12.09 (s, 1H), 10.68 (s, 1H), 8.34 (s, 1H), 7.68-7.86 (m, 
5H), 7.17-7.29 (m, 3H), 7.01-7.10 (m, 2H), 4.06 (q, J = 7.0 Hz, 2H), 1.30 (t, J = 1.3 Hz, 
3H); MS (ESI) C20H19N4O7S [MH]+ m/z expected = 459.1, observed = 459.0; HPLC-1 = 
97%; HPLC-2 = 97%. 
 .......................................................................................................................................... 
N'-((4-hydroxynaphthalen-1-yl)methylene)-4-methoxybenzohydrazide (29).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.57 (s, 1H), 10.75 (s, 1H), 8.82-8.99 (m, 2H), 8.20 (d, 
J = 8.1 Hz, 1H), 7.84-7.99 (m, 2H), 7.69 (d, J = 7.8 Hz, 1H), 7.61 (t, J = 7.5 Hz, 1H), 7.50 
(t, J = 7.5 Hz, 1H), 6.99-7.11 (m, 2H), 6.93 (d, J = 7.9 Hz, 1H), 3.81 (s, 3H); MS (ESI) 
47 
C19H17N2O3 [M-H]- m/z expected = 321.1, observed = 321.1; HPLC-1 = 99%; HPLC-2 = 
99%. 
 .......................................................................................................................................... 
N'-((4-hydroxynaphthalen-1-yl)methylene)benzohydrazide (30).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.72 (s, 1H), 10.81 (s, 1H), 8.89-9.02 (m, 2H), 8.24 (d, 
J = 8.1 Hz, 1H), 7.95 (d, J = 7.2 Hz, 2H), 7.74 (d, J = 8.1 Hz, 1H), 7.48-7.70 (m, 5H), 
6.97 (d, J = 7.9 Hz, 1H); MS (ESI) C18H15N2O2 [MH]+ m/z expected = 291.1, observed = 
291.1; HPLC-1 = 99%; HPLC-2 = 98%. 
 .......................................................................................................................................... 
4-methoxy-N'-(quinolin-5-ylmethylene)benzohydrazide (31).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.91 (s, 1H), 9.45 (d, J = 8.3 Hz, 1H), 8.98 (d, J = 3.9 
Hz, 2H), 8.10 (d, J = 8.1 Hz, 1H), 7.91-8.02 (m, 3H), 7.80-7.89 (m, 1H), 7.68 (dd, J = 8.1, 
3.7 Hz, 1H), 7.10 (d, J = 8.8 Hz, 2H), 3.85 (s, 3H); MS (ESI) C18H16N3O2 [MH]+ m/z 
expected = 306.1, observed = 306.1; HPLC-1 = 99%; HPLC-2 = 99%. 
 .......................................................................................................................................... 
N'-(quinolin-5-ylmethylene)benzohydrazide (32).   
 
1H-NMR (300 MHz, d6-DMSO) δ 12.05 (s, 1H), 9.45 (d, J = 8.5 Hz, 1H), 8.93-9.06 (m, 
2H), 8.10 (d, J = 8.2 Hz, 1H), 7.97 (t, J = 7.5 Hz, 3H), 7.80-7.89 (m, 1H), 7.69 (dd, J = 
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8.7, 4.0 Hz, 1H), 7.50-7.64 (m, 3H); MS (ESI) C17H14N3O [MH]+ m/z expected = 276.1, 
observed = 276.1; HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
4-methoxy-N'-(naphthalen-1-ylmethylene)benzohydrazide (33).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.83 (s, 1H), 9.10 (s, 1H), 8.87 (d, J = 8.2 Hz, 1H), 
8.02 (d, J = 7.9 Hz, 2H), 7.89-7.99 (m, 3H), 7.57-7.72 (m, 3H), 7.06-7.13 (m, 2H), 3.85 
(s, 3H); MS (ESI) C19H17N2O2 [MH]+ m/z expected = 305.1, observed = 305.1; HPLC-1 = 
f>99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
N'-(naphthalen-1-ylmethylene)benzohydrazide (34).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.96 (s, 1H), 9.12 (s, 1H), 8.88 (d, J = 8.3 Hz, 1H), 
8.03 (dd, J = 7.7, 3.2 Hz, 2H), 7.91-8.00 (m, 3H), 7.52-7.73 (m, 6H); MS (ESI) C18H15N2O 
[MH]+ m/z expected = 275.1, observed = 275.0; HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
N'-(4-hydroxybenzylidene)-4-methoxybenzohydrazide (35).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.53 (s, 1H), 9.93 (s, 1H), 8.33 (s, 1H), 7.89 (d, J = 8.8 
Hz, 2H), 7.50-7.59 (m, 2H), 7.00-7.09 (m, 2H), 6.83 (d, J = 8.5 Hz, 2H), 3.83 (s, 3H); MS 
(ESI) C15H15N2O3 [MH]+ m/z expected = 271.1, observed = 271.1; HPLC-1 = 95%; 
HPLC-2 = 99%. 
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 .......................................................................................................................................... 
N'-(4-hydroxybenzylidene)benzohydrazide (36).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.65 (s, 1H), 9.95 (s, 1H), 8.34 (s, 1H), 7.89 (d, J = 6.8 
Hz, 2H), 7.44-7.64 (m, 5H), 6.84 (d, J = 8.6 Hz, 2H); MS (ESI) C14H13N2O2 [MH]+ m/z 
expected = 241.1, observed = 241.1; HPLC-1 = 95%; HPLC-2 = 98%. 
 .......................................................................................................................................... 
N'-benzylidene-4-methoxybenzohydrazide (37).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.74 (s, 1H), 8.45 (s, 1H), 7.87-7.96 (m, 2H), 7.67-
7.77 (m, 2H), 7.39-7.51 (m, 3H), 7.02-7.11 (m, 2H), 3.83 (s, 3H); MS (ESI) C15H15N2O2 
[MH]+ m/z expected = 255.1, observed = 255.1; HPLC-1 = 99%; HPLC-2 = 99%. 
 .......................................................................................................................................... 
N'-benzylidenebenzohydrazide (38).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.87 (s, 1H), 8.47 (s, 1H), 7.92 (d, J = 7.0 Hz, 2H), 
7.69-7.78 (m, 2H), 7.41-7.64 (m, 6H); MS (ESI) C14H13N2O [MH]+ m/z expected = 225.1, 
observed = 225.1; HPLC-1 = >99%; HPLC-2 = >99%. 
 .......................................................................................................................................... 
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N'-(furan-2-ylmethylene)-4-methoxybenzohydrazide (39).   
 
1H-NMR (300 MHz, d6-DMSO) δ 11.68 (s, 1H), 8.33 (s, 1H), 7.86-7.92 (m, 2H), 7.84 (s, 
1H), 7.02-7.10 (m, 2H), 6.91 (d, J = 3.1 Hz, 1H), 6.63 (dd, J = 3.3, 1.7 Hz, 1H), 3.83 (s, 
3H); MS (ESI) C13H13N2O3 [MH]+ m/z expected = 245.1, observed = 245.1; HPLC-1 = 
98%; HPLC-2 = 98%. 
 
General materials and methods for biochemical and cell-based experiments 
   
NEB 5-alpha (a derivative of DH5α E. coli) and BL21 (DE3) E. coli cells were 
purchased from New England Biolabs, and Rosetta™ 2 (DE3) E. coli cells were 
purchased from EMD Millipore.  The human cell viability assays used FHC colon cells 
(CRL-1831) and FHs 74 Int small intestine cells (CCL-241) obtained from the ATCC.  
Ampicillin was used at a concentration of 50 μg/mL, when appropriate. 
 
NOTE:  While the following experimental protocols have been reported in previous 
studies, detailed descriptions are included in an effort to maintain rigor, reproducibility, 
and transparency throughout these studies.28,31,33,50-51 
 
E. coli GroEL and GroES purification  
E. coli GroEL was expressed from a trc-promoted and Amp(+) resistance marker 
plasmid in NEB 5-alpha E. coli cells.  GroES was expressed from a T7-promoted and 
Amp(+) resistance plasmid in E. coli BL21 (DE3) cells.  Transformed colonies were 
plated onto Ampicillin-treated LB agar and incubated overnight at 37°C.  A single colony 
was selected and grown in LB media treated with Ampicillin for 16 hours at 37°C at 200 
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rpm.  Cells were then sub-cultured in scaled-up Ampicillin-treated LB medium and grown 
at 37°C at 230 rpm until an OD600 of 0.5 was reached, then were induced with 0.8 mM 
IPTG and continued to grow for ~2.5 h at 37°C.  The cultures were centrifuged at 8,000 
rpm at 4°C and the cell pellets were collected and re-suspended in Buffer A (50 mM Tris-
HCl, pH 7.4, and 20 mM NaCl) supplemented with EDTA-free complete protease 
inhibitor cocktail (Roche).  The combined suspension was lysed by sonication, the lysate 
was centrifuged at 14,000 rpm at 4°C, and the clarified lysate was passed through a 
0.45 μm filter (Millipore). 
 
Anion exchange purification of GroEL: The filtered lysate was loaded onto a GE 
HiScale Anion exchange column (Q Sepharose fast flow anion exchange resin) that was 
equilibrated with 2 column volumes of Buffer A.  The loaded column was washed with 3 
column volumes of Buffer A containing 28% of Buffer B (50 mM Tris-HCl, pH 7.4, and 1 
M NaCl), then bound protein was eluted with a 28-60% gradient elution of Buffer B over 
3 column volumes.  Protein-containing fractions, as identified by SDS-PAGE, were 
collected, spin concentrated using a 10 kDa Amicon Ultra-15 centrifugal filter (EMD 
Millipore), and dialyzed overnight with 10 kDa SnakeSkin™ dialysis tubing (Thermo 
Scientific) at 4°C in 50 mM Tris-HCl, pH 7.4, and 150 mM NaCl solution.  
 
Size exclusion chromatography of GroEL:  The dialyzed protein was loaded onto 
a Superdex 200 size exclusion column (HiLoad 26/600, GE) that was equilibrated with 2 
column volumes of 50 mM Tris-HCl, pH 7.4, and 150 mM NaCl solution.  The loaded 
column was eluted with 1 column volume of 50 mM Tris-HCl, pH 7.4, and 150 mM NaCl 
solution.  Protein-containing fractions, as identified by SDS-PAGE, were collected, spin 
concentrated using a 10 kDa Amicon Ultra-15 centrifugal filter (EMD Millipore), and 
dialyzed overnight with 10 kDa SnakeSkinTM dialysis tubing (Thermo Scientific) at 4°C in 
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50 mM Tris-HCl, pH 7.4, and 150 mM NaCl solution.  The final protein concentration was 
determined by Coomassie Protein Assay Kit (Thermo Scientific). Batches of GroEL 
protein for testing were stored at 4°C for up to one month, then discarded. 
 
Anion exchange purification of GroES: The filtered lysate was loaded onto a GE 
HiScale anion exchange column (Q Sepharose fast flow anion exchange resin) that was 
equilibrated with 2 column volumes of Buffer A.  The loaded column was washed with 3 
column volumes of Buffer A containing 10% of Buffer B (50 mM Tris-HCl, pH 7.4, and 1 
M NaCl), then bound protein was eluted with a 10-50% gradient elution of Buffer B over 
3 column volumes.  Protein-containing fractions, as identified by SDS-PAGE, were 
collected, spin concentrated using a 10 kDa Amicon Ultra-15 centrifugal filter (EMD 
Millipore), and dialyzed overnight with 10 kDa SnakeSkin™ dialysis tubing (Thermo 
Scientific) at 4°C in 50 mM Tris-HCl, pH 7.4, and 150 mM NaCl solution.  
 
Size exclusion chromatography of GroES: The dialyzed protein was loaded onto 
a Superdex 200 size exclusion column (HiLoad 26/600, GE) that was equilibrated with 2 
column volumes of 50 mM Tris-HCl, pH 7.4, and 150 mM NaCl solution.  The loaded 
column was eluted with 1 column volume of 50 mM Tris-HCl, pH 7.4, and 150 mM NaCl 
solution.  Protein-containing fractions, as identified by SDS-PAGE, were collected, spin 
concentrated using a 10 kDa Amicon Ultra-15 centrifugal filter (EMD Millipore), and 
dialyzed overnight with 10 kDa SnakeSkinTM dialysis tubing (Thermo Scientific) at 4°C in 
50 mM Tris-HCl, pH 7.4, and 150 mM NaCl solution.  The final protein concentration was 
determined by Coomassie Protein Assay Kit (Thermo Scientific). Batches of GroES 
protein for testing were stored at 4°C for up to one month, then discarded. 
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Evaluation of compounds in the GroEL/ES-mediated dMDH refolding assays 
Reagent preparation: For these assays, four primary reagent stocks were 
prepared: 1) GroEL/ES-dMDH binary complex stock; 2) ATP initiation stock; 3) EDTA 
quench stock; 4) MDH enzymatic assay stock.  Denatured MDH (dMDH) was prepared 
by 2-fold dilution of MDH (5 mg/ml, soluble pig heart MDH from Roche, product 
#10127248001) with denaturant buffer (7 M guanidine-HCl, 200 mM Tris, pH 7.4, and 50 
mM DTT).  MDH was completely denatured by incubating at room temperature for >45 
min.  The binary complex solutions were prepared by slowly adding the dMDH stock to a 
stirring stock with GroEL and GroES in folding buffer (50 mM Tris-HCl, pH 7.4, 50 mM 
KCl, 10 mM MgCl2, and 1 mM DTT).  The binary complex stocks were prepared 
immediately prior to dispensing into the assay plates and had final protein 
concentrations of 83.3 nM GroEL, 100 nM GroES, and 20 nM dMDH in folding buffer.  
For the ATP initiation stock, ATP solid was diluted into folding buffer to a final 
concentration of 2.5 mM.  Quench solution contained 600 mM EDTA (pH 8.0).  The MDH 
enzymatic assay stock consisted of 20 mM sodium mesoxalate and 1.6 mM NADH in 
reaction buffer (50 mM Tris-HCl, pH 7.4, 50 mM KCl, and 1 mM DTT). 
 
Assay Protocol: First, 30 µL aliquots of the GroEL/ES-dMDH binary complex 
stocks were dispensed into clear, 384-well polystyrene plates.  Next, 0.5 µL of the 
compound stocks (10 mM to 4.6 µM, 3-fold dilutions series in DMSO) were added by 
pin-transfer (V&P Scientific).  The chaperonin-mediated refolding cycles were initiated by 
addition of 20 µL of ATP stock (reagent concentrations during refolding cycle: 50 nM 
GroEL, 60 nM GroES, 12 nM dMDH, 1 mM ATP, and compounds of 100 µM to 46 nM, 3-
fold dilution series) and the refolding reactions were incubated at 37°C. The incubation 
time was determined from refolding time-course control experiments until they reached 
~90% completion of the refolding of dMDH – generally ~20-40 min.  Next, the assay was 
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quenched by addition of 10 µL of the EDTA stock to give a final concentration of 100 mM 
in the wells.  Enzymatic activity of the refolded MDH was initiated by addition of 20 µL 
MDH enzymatic assay stock, and followed by measuring the NADH absorbance in each 
well at 340 nm using a Molecular Devices SpectraMax Plus384 microplate reader 
(NADH absorbs at 340 nm, while NAD+ does not).  A340 nm measurements were recorded 
at 0.5 minutes (start point) and at successive time points until the amount of NADH 
consumed reached ~90% (end point, generally between 20-35 minutes).  The ratio 
between start and end point A340 values were used to calculate the % inhibition of the 
GroEL/ES machinery by the compounds  IC50 values for the test compounds were 
obtained by plotting the % inhibition results in GraphPad Prism and analyzing by non-
linear regression using the log(inhibitor) vs. response (variable slope) equation.  Results 
presented represent the averages of IC50 values obtained from at least four replicates in 
the GroEL/ES-dMDH refolding assay. 
 
Counter-screening compounds for inhibition of native MDH enzymatic activity 
Reagent Preparations & Assay Protocol:  This assay was performed as 
described above for the GroEL/ES-dMDH refolding assay; however, the assay protocol 
differed in the sequence of compound addition to the assay plates.  The refolding 
reactions were allowed to proceed for 45 min at 37°C in the absence of test compounds 
(complete refolding of MDH occurs), then quenched with the EDTA stock.  Compounds 
were then pin-transferred into the plates after the EDTA quenching step; thus, 
compound effects are only possible by inhibiting the fully-refolded MDH reporter 
substrate.  Next, enzymatic activity of the refolded MDH was initiated by addition of 20 
µL MDH enzymatic assay stock and followed by measuring the NADH absorbance in 
each well at 340 nm using a Molecular Devices SpectraMax Plus384 microplate reader 
(NADH absorbs at 340 nm, while NAD+ does not).  A340 nm measurements were recorded 
55 
at 0.5 minutes (start point) and at successive time points until the amount of NADH 
consumed reached ~90% (end point, generally between 20-35 minutes). Compounds 
were tested in 8-point, 3-fold dilution series (62.5 µM to 29 nM during the reporter 
reaction) in clear, flat-bottom 384-well microtiter plates.  IC50 values for the MDH reporter 
enzyme were determined as described above.  Results presented represent the 
averages of IC50 values obtained from at least five replicates. 
 
Evaluation of compounds in the GroEL/ES-mediated dMDH refolding assay and 
native MDH activity counter-screen in the presence of E. coli NfsB nitroreductase   
These assays were performed nearly identically to those described above, but 
with a couple distinct modifications.  For both assays, 10 μg/mL of the E. coli NfsB 
nitroreductase enzyme (Sigma product #N9284) was added to the initial GroEL/ES-
dMDH solution.  For the GroEL/ES-dMDH refolding assay, after stamping with 
compounds, 10 μL of a 2.4 mM NADH solution was added, followed by a 10 minute 
incubation period at 37°C to bioactivate the nitrofuran analogues.  The remainder of the 
assay was conducted as above in the absence of the NfsB nitroreductase.  With the 
extra 10 μL volume from the NADH addition, this made the compound concentrations 
during the refolding cycle part of the assay range from 83 µM to 38 nM (3-fold dilution 
series).  For the native MDH activity counter-screen in the presence of E. coli NfsB 
nitroreductase, the assay was performed as described above for the GroEL/ES-dMDH 
refolding assay with NfsB; however, the compound addition to the assay plates was 
conducted after the EDTA quench step, followed by a 10 minute incubation period at 
37°C to bioactivate the nitrofuran analogues.  With the extra 10 μL volume from the 
NADH addition, this made the compound concentrations during the enzymatic reporter 
part of the assay range from 56 µM to 25 nM (3-fold dilution series).  IC50 values for the 
test compounds were obtained by plotting the % inhibition results in GraphPad Prism 
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and analyzing by non-linear regression using the log(inhibitor) vs. response (variable 
slope) equation.  Results presented represent the averages of IC50 values obtained from 
at least four replicates in each assay. 
 
Evaluation of compounds for inhibition in the GroEL/ES-mediated dRho refolding 
assay 
Reagent preparation:  For this assay, five primary reagent stocks were prepared: 
1) GroEL/ES-dRho binary complex stock; 2) ATP initiation stock; 3) thiocyanate 
enzymatic assay stock; 4) formaldehyde quench stock; 5) ferric nitrate reporter stock.  
Denatured rhodanese (dRho) was prepared by 3-fold dilution of rhodanese (Roche 
product #R1756, diluted to 10 mg/mL with H2O) with denaturant buffer (12 M Urea, 50 
mM Tris-HCl, pH 7.4, and 10 mM DTT).  Rhodanese was completely denatured by 
incubating at room temperature for >45 min.  The binary complex solution was prepared 
by slowly adding the dRho stock to a stirring stock of concentrated GroEL in modified 
folding buffer (50 mM Tris-HCl, pH 7.4, 50 mM KCl, 10 mM MgCl2, 5 mM Na2S2O3, and 1 
mM DTT).  The solution was centrifuged at 16,000 x g for 5 minutes, and the 
supernatant was collected and added to a solution of GroES in modified folding buffer to 
give final protein concentrations of 100 nM GroEL, 120 nM GroES, and 80 nM dRho.  
The binary complex stock was prepared immediately prior to use.  For the ATP initiation 
stock, ATP solid was diluted into modified folding buffer to a final concentration of 2.0 
mM.  The thiocyanate enzymatic assay stock was prepared to contain 70 mM KH2PO4, 
80 mM KCN, and 80 mM Na2S2O3 in water.  The formaldehyde quench solution 
contained 30% formaldehyde in water.  The ferric nitrate reporter stock contained 8.5% 
w/v Fe(NO3)3 and 11.3% v/v HNO3 in water. 
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Assay Protocol:  First, 10 L aliquots of the GroEL/ES-dRho complex stock were 
dispensed into clear, flat-bottom 384-well polystyrene plates.  Next, 0.5 µL of the 
compound stocks (10 mM to 4.6 µM, 3-fold dilutions in DMSO) were added by pin-
transfer.  The chaperonin-mediated refolding cycle was initiated by addition of 10 µL of 
ATP stock (reagent concentrations during refolding cycle: 50 nM GroEL, 60 nM GroES, 
40 nM dRho, 1 mM ATP, and compounds of 250 µM to 114 nM, 3-fold dilution series).  
After incubating for 40 minutes at 37°C for the refolding cycle, 30 µL of the thiocyanate 
enzymatic assay stock was added and incubated for 60 min at room temperature for the 
refolded rhodanese enzymatic reporter reaction.  The reporter reaction was quenched by 
adding 10 µL of the formaldehyde quench stock, and then 40 µL of the ferric nitrate 
reporter stock was added to quantify the amount of thiocyanate produced during the 
enzymatic reporter reaction, which is proportional to the amount of dRho refolded by 
GroEL/ES.  After incubating at room temperature for 15 min, the absorbance by 
Fe(SCN)3 was measured at 460 nm using a Molecular Devices SpectraMax Plus384 
microplate reader.  A second set of baseline control plates were prepared analogously, 
but without GroEL/ES-dRho protein binary solution, to correct for possible interference 
from compound absorbance or turbidity.  IC50 values for the test compounds were 
obtained by plotting the A460 results in GraphPad Prism and analyzing by non-linear 
regression using the log(inhibitor) vs. response (variable slope) equation.  Results 
presented represent the averages of IC50 values obtained from at least four replicates. 
 
Counter-screening compounds for inhibition of native rhodanese enzymatic 
activity 
Reagent Preparations & Assay Protocol:  Reagents were identical to those used 
in the GroEL/ES-dRho refolding assay described above; however, the assay protocol 
differed in the sequence of compound addition to the wells.  Compounds were pin-
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transferred after 50 minute incubation for the refolding cycle, but prior to the addition of 
the thiocyanate enzymatic assay stock.  Thus, the refolding reactions were allowed to 
proceed for 50 min at 37°C in the absence of test compounds, but the enzymatic activity 
of the refolded rhodanese reporter enzyme was monitored in the presence of test 
compounds (inhibitor concentration range during the enzymatic reporter reaction is 100 
µM to 46 nM – 3-fold dilutions).  IC50 values for the rhodanese reporter enzyme were 
determined as described above.  Results presented represent the averages of IC50 
values obtained from at least four replicates. 
 
Evaluation of compounds for inhibition in the GroEL-mediated ATPase assay 
Reagent preparation:  For this assay, four primary reagent solutions were 
prepared: 1) GroEL protein solution; 2) ATP initiation solution; 3) EDTA quench solution; 
4) malachite green reporter solution.  The GroEL protein solution consisted of 100 nM of 
GroEL in folding buffer (50 mM Tris-HCl, pH 7.4, 50 mM KCl, 10 mM MgCl2, and 1 mM 
DTT), which was prepared immediately prior to dispensing into the assay plates.  For the 
ATP initiation solution, ATP solid was diluted into folding buffer to a final concentration of 
2 mM.  Quench solution contained 300 mM EDTA (pH 8.0).  The malachite green 
reporter solution contained 0.034% w/v malachite green, 1.04% w/v ammonium 
molybdate, 1% Tween-20, and 1 M HCl dissolved in H2O. 
 
Assay Protocol:  First, 10 µL aliquots of the GroEL protein solution were 
dispensed into clear, flat-bottom 384-well polystyrene plates.  Next, 0.5 µL of the 
compound stocks (10 mM to 4.6 µM, 3-fold dilutions in DMSO) were added by pin-
transfer.  GroEL-mediated ATPase activity was initiated by addition of 10 µL of ATP 
solution (compound concentrations during the assay ranged from 250 µM to 114 nM).  
After incubating for 45 minutes at 37°C, 10 µL of the EDTA quench solution was added 
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to quench the reaction cycle.  Then, 60 µL of the malachite green reporter solution was 
added and the plates were incubated at room temperature for 10 min.  The absorbance 
of the malachite green-phosphate complex was measured at 600 nm using a Molecular 
Devices SpectraMax Plus384 microplate reader.  A second set of baseline control plates 
were prepared analogously, but without GroEL protein solution, to correct for possible 
interference from compound absorbance or turbidity.  IC50 values for the test compounds 
were obtained by plotting the A600 results in GraphPad Prism and analyzing by non-linear 
regression using the log(inhibitor) vs. response (variable slope) equation.  Results 
presented represent the averages of IC50 values obtained from at least four replicates. 
 
Evaluation of compounds for inhibition of bacterial cell proliferation  
Bacterial Strains: NEB 5-alpha Escherichia coli (a derivative of DH5α E. coli, New 
England Biolabs #C2987H); Enterococcus faecium - (Orla-Jensen) Schleifer and 
Kilpper-Balz strain NCTC 7171 (ATCC #19434); Staphylococcus aureus - Rosenbranch 
strain Seattle 1945 (ATCC #25923); Klebsiella pneumoniae - (Schroeter) Trevisan strain 
NCTC 9633 (ATCC #13883); Acinetobacter baumannii - Bouvet and Grimont strain 2208 
(ATCC 19606); Pseudomonas aeruginosa - (Schroeter) Migula strain NCTC 10332 
(ATCC #10145); Enterobacter cloacae - E. cloacae, subsp. cloacae (Jordan) Hormaeche 
and Edwards strain CDC 442-68 (ATCC #13047).  
 
Growth Media: E. coli were grown with LB medium and all ESKAPE bacteria 
were grown in Brain Heart Infusion (BHI) medium (Becton, Dickinson and Company), 
with all liquid cultures supplemented with 25 mg/L Ca2+ and 12.5 mg/L Mg2+ to mimic 
physiological free concentrations of these cations.32 A 10 mg/mL Ca2+ stock solution was 
prepared by dissolving 1.84 g of CaCl2·2H2O in 50 mL of deionized water, and a 10 
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mg/mL Mg2+ stock solution was prepared by dissolving 4.18 g of MgCl2·6H2O in 50 mL 
deionized water – filter sterilized using 0.2 µm cellulose-acetate filters.  2.5 mL of the 
sterile 10 mg/mL Ca2+ stock and 1.25 mL of the sterile 10 mg/mL Mg2+ stock solutions 
were added per 1 L of autoclaved LB or BHI media to obtain 25 mg/L Ca2+ and 12.5 
mg/L Mg2+ ions, respectively.  
 
General Assay Protocol: Stock bacterial cultures were streaked onto LB or BHI 
agar plates and grown overnight at 37°C.  Fresh aliquots of cation supplemented media 
were inoculated with single bacterial colonies and the cultures were grown overnight at 
37°C with shaking (240 rpm).  The following morning, cultures were diluted 10-fold into 
fresh media and grown at 37°C until bacteria had reached mid-log phase growth (OD600 
~ 0.4-0.6).  The cultures were then diluted into fresh media to achieve final OD600 
readings of 0.017.  Aliquots of these diluted cultures (30 µL) were added to clear, flat-
bottom 384-well polystyrene plates that were previously stamped with 0.5 µL of test 
compounds in 20 µL of media (yielding initial OD600 = 0.01 bacterial cultures).  All 
compounds were tested in dose-response with concentration ranges during the 
proliferation assays from 100 µM to 46 nM (3-fold dilution series).  A second set of 
baseline control plates were prepared analogously, but without any bacteria added, to 
correct for possible compound absorbance and/or precipitation. Plates were sealed with 
"Breathe Easy" oxygen permeable membranes (Diversified Biotech) and left to incubate 
at 37°C without shaking (stagnant assay) until the bacteria had reached mid-log phase 
growth. Plates were then read at 600 nm using a Molecular Devices SpectraMax 
Plus384 microplate reader.  EC50 values for the test compounds were obtained by 
plotting the OD600 results in GraphPad Prism and analyzing by non-linear regression 
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using the log(inhibitor) vs. response (variable slope) equation.  Results presented 
represent the averages of EC50 values obtained from at least four replicates. 
 
Evaluating compounds for effects on the viability of healthy human colon (FHC) 
and small intestine (FHs 74 Int) cells  
Evaluation of compound cytotoxicities to FHC colon and FHs 74 Int small 
intestine cells were performed using Alamar Blue-based viability assays.  FHC cells 
were maintained in Hyclone DMEM:F12 1:1 medium containing L-glutamine and 
supplemented with 10 mM HEPES, 10 ng/mL cholera toxin, 0.005 mg/mL insulin, 0.005 
mg/mL transferrin, 100 ng/mL hydrocortisone, and 10% FBS (Midwest Scientific, 
USDAFBS).  FHs 74 Int cells were maintained in Hybri-care medium (ATCC 46-X) 
supplemented with 30 ng/mL recombinant epidermal growth factor (EGF) and 10% FBS 
(Midwest Scientific, USDAFBS).  All assays were carried out in 384-well plates (BRAND 
cell culture grade plates, 781980).  Cells at 90% confluence were harvested and diluted 
in growth medium, then 45 µL of the FHC cells (1,500 cells/well) or FHs 74 Int cells 
(1,500 cells/well) were dispensed per well.  Plates were sealed with "Breathe Easy" 
oxygen permeable membranes (Diversified Biotech) and incubated at 37°C, 5% CO2, for 
24 h.  The following day, 1 µL of the compound stocks (10 mM to 4.6 µM, 3-fold dilutions 
in DMSO) were pre-diluted by pin-transfer into 25 µL of the respective growth media, 
then 15 µL aliquots of these solutions were added to the cell assay plates to give 
inhibitor concentration ranges of 100 µM to 46 nM during the assay (final DMSO 
concentration of 1% was maintained during the assay).  Plates were sealed with 
"Breathe Easy" oxygen permeable membranes and incubated for an additional 48 h at 
37°C and 5% CO2.  The Alamar Blue reporter reagents were then added to a final 
concentration of 10%, and the plates incubated at 37°C and 5% CO2 while the reporter 
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reagents developed.  Sample fluorescence (535 nm excitation, 590 nm emission) was 
read over time using a Molecular Devices FlexStation II 384-well plate reader (readings 
taken between 4-24 h of incubation so as to achieve signals in the 30-60% range for 
conversion of resazurin to resorufin).  Cell viability was calculated as per vendor 
instructions (Thermo Fisher - Alamar Blue cell viability assay manual).  Cytotoxicity CC50 
values for the test compounds were obtained by plotting the % resazurin reduction 
results in GraphPad Prism and analyzing by non-linear regression using the log(inhibitor) 
vs. response (variable slope) equation.  Results presented represent the averages of 
CC50 values obtained from at least four replicates for each of the FHC and FHs 74 Int 
cell lines. 
 
Evaluation of E. coli resistance generation against lead inhibitors 
To identify potential resistance toward 17, nifuroxazide, and nitrofurantoin, a 
liquid culture, 12-day serial passage assay was employed (each compound was tested 
in duplicate).  NEB 5-alpha E. coli bacteria were streaked onto an LB agar plate and 
grown overnight at 37°C.  Two fresh aliquots of LB media (supplemented with 25 mg/L 
Ca2+ and 12.5 mg/L Mg2+) were inoculated with separate bacterial colonies and the 
cultures were grown overnight at 37°C, with shaking (240 rpm).  The overnight cultures 
were then sub-cultured (10x dilution) into fresh media solutions and grown at 37°C to 
mid-log phase, then diluted into fresh media to achieve two separate cultures with final 
OD600 readings of 0.01.  Aliquots of the diluted cultures (200 µL) were dispensed into a 
clear, 96-well polystyrene plate (one culture was used for replicate 1 for each compound, 
and the other culture was used for replicate 2 for each compound), followed by the 
addition of 2 µL of nifuroxazide, nitrofurantoin, and compound 17 in DMSO.  Test 
compounds were evaluated in duplicate with concentration ranges during the resistance 
assay from 100 µM to 48.8 nM, 2-fold dilution series. Plates were sealed with "Breathe 
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Easy" oxygen permeable membranes (Diversified Biotech) and left to incubate at 37°C 
without shaking (stagnant assay).  OD600 readings were taken at the 24 h time point to 
monitor for bacterial growth.  A second baseline control plate was prepared analogously, 
without any bacteria added, to correct for possible compound absorbance and/or 
precipitation.  For inoculations on subsequent days, bacteria from the wells with the 
highest test compound concentration where the OD600 was >0.2, were sub-cultured in 5 
mL of fresh media at 37°C until mid-log phase growth was reached.  Separate cultures 
were maintained from this point forward for each of the compound replicates – i.e. 6 
cultures continually propagated.  The bacteria were then diluted into fresh media to  
OD600 of 0.01 and the bacteria were propagated again as described above.  This 
procedure was repeated each day, for a total of 12 days, to observe changes in inhibitor 
EC50 values over each passage (aliquots of each of these daily cultures were flash 
frozen in liquid nitrogen and stored at -80°C for future use).  Inhibitor EC50 values were 
obtained by plotting the OD600 results from each passage in GraphPad Prism and 
analyzing by non-linear regression using the log(inhibitor) vs. response (variable slope) 
equation. 
 
Control compounds, calculation of IC50 / EC50 / CC50 values, and statistical 
considerations 
For all assays, DMSO was used as negative control and a panel of previously 
discovered and reported chaperonin inhibitors were used as positive controls: e.g. 
compounds 8, 9, and 18 from Johnson et. al 2014 and Abdeen et. al 2016;28,33 suramin 
and compound 2h-p from Abdeen et. al 2016;28 compounds 20R, 20L, and 28R from 
Abdeen et. al 2018;31 and closantel and rafoxanide from Kunkle et. al 2018.32 Bacterial 
proliferation assays also included antibiotic controls such as vancomycin, daptomycin, 
and rifampicin.  All IC50 / EC50 / CC50 results reported are averages of values determined 
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from individual dose-response curves in assay replicates as follows: 1) individual 
I/E/CC50 values from assay replicates were first log-transformed and the average 
log(I/E/CC50) values and standard deviations (SD) calculated; 2) replicate log(I/E/CC50) 
values were evaluated for outliers using the ROUT method in GraphPad Prism (Q of 
10%); and 3) average I/E/CC50 values were then back-calculated from the average 
log(I/E/CC50) values.  For compounds where log(I/E/CC50) values were greater than the 
maximum compound concentrations tested (i.e. >1.75, >1.80, >1.92, >2.00, and >2.40 – 
or >56, >63, >83, >100, and >250 µM, respectively), results were represented as 0.1 log 
units higher than the maximum concentrations tested (i.e. 1.85, 1.90, 2.02, 2.10, and 
2.50 – or 71, 79, 105, 126, and 316 µM, respectively) so as not to overly bias results 
because of the unavailability of definitive values for inactive compounds.   
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APPENDIX - SUPPLEMENTAL TABLES 
Table 2A - Bacterial proliferation EC50 (µM) Compilation of EC50 results for compounds tested 
in the various bacterial proliferation assays. 
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Table 2B - Bacterial proliferation log(EC50) (µM) Compilation of log(EC50) results and standard 
deviations for compounds tested in the various bacterial proliferation assays. 
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Table 3A - Biochemical assay IC50 (µM) Compilation of IC50 results for compounds tested in the 
GroEL/ES-mediated dMDH and dRho refolding assays, native MDH and Rho reporter counter-
screens, and GroEL-mediated ATPase assay. 
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Table 3B - Biochemical assay log(IC50) (µM) Compilation of log(IC50) results and standard 
deviations for compounds tested in the GroEL/ES-mediated dMDH and dRho refolding assays, 
native MDH and Rho reporter counter-screens, and GroEL-mediated ATPase assay. 
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Table 4A - Biochemical assay IC50 (µM) with and without nitroreductase Compilation of IC50 
results for compounds tested in the GroEL/ES-mediated dMDH assay and native MDH counter-
screen, in the presence and absence of E. coli NfsB nitroreductase (NR).  
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Table 4B - Biochemical assay log(IC50) (µM) with and without nitroreductase Compilation of 
log(IC50) results and standard deviations for compounds tested in the GroEL/ES-mediated dMDH 
assay and native MDH counter-screen, in the presence and absence of E. coli NfsB 
nitroreductase (NR). 
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Table 5A - Human cell viability CC50 (µM) Compilation of CC50 results for compounds tested in 
the human FHC colon and FHs 74 Int intestine cell viability assays.  
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Table 5B - Human cell viability log(CC50) (µM) Compilation of log(CC50) results and standard 
deviations for compounds tested in the human FHC colon and FHs 74 Int intestine cell viability 
assays. 
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